KR100975426B1 - Composition comprising the crude extract for preventing and treating allergic skin diseases - Google Patents
Composition comprising the crude extract for preventing and treating allergic skin diseases Download PDFInfo
- Publication number
- KR100975426B1 KR100975426B1 KR1020080032336A KR20080032336A KR100975426B1 KR 100975426 B1 KR100975426 B1 KR 100975426B1 KR 1020080032336 A KR1020080032336 A KR 1020080032336A KR 20080032336 A KR20080032336 A KR 20080032336A KR 100975426 B1 KR100975426 B1 KR 100975426B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- extract
- atopic dermatitis
- herbal
- Prior art date
Links
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title abstract description 70
- 208000017520 skin disease Diseases 0.000 title abstract description 24
- 230000000172 allergic effect Effects 0.000 title abstract description 19
- 239000000287 crude extract Substances 0.000 title 1
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 116
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 106
- 239000000284 extract Substances 0.000 claims abstract description 92
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 208000002474 Tinea Diseases 0.000 claims abstract description 13
- 241000893966 Trichophyton verrucosum Species 0.000 claims abstract description 13
- 210000002540 macrophage Anatomy 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000002537 cosmetic Substances 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 16
- 235000015872 dietary supplement Nutrition 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 11
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 10
- 241000411851 herbal medicine Species 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 241000287509 Piciformes Species 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 5
- 235000008434 ginseng Nutrition 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 229940010454 licorice Drugs 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 244000246386 Mentha pulegium Species 0.000 claims description 4
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 4
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 4
- 235000001050 hortel pimenta Nutrition 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 241000234282 Allium Species 0.000 claims description 2
- XAQHXGSHRMHVMU-UHFFFAOYSA-N [S].[S] Chemical compound [S].[S] XAQHXGSHRMHVMU-UHFFFAOYSA-N 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 235000002789 Panax ginseng Nutrition 0.000 claims 2
- 239000004575 stone Substances 0.000 claims 2
- 241000208340 Araliaceae Species 0.000 claims 1
- 241000286209 Phasianidae Species 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- 229910052956 cinnabar Inorganic materials 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- 239000012676 herbal extract Substances 0.000 abstract description 61
- 238000012360 testing method Methods 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 29
- 241001465754 Metazoa Species 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 230000001953 sensory effect Effects 0.000 abstract description 16
- 230000002829 reductive effect Effects 0.000 abstract description 7
- 241000699670 Mus sp. Species 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 208000024891 symptom Diseases 0.000 description 26
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 22
- 229960003957 dexamethasone Drugs 0.000 description 22
- 238000011156 evaluation Methods 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 21
- 238000009472 formulation Methods 0.000 description 20
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 19
- 108090000978 Interleukin-4 Proteins 0.000 description 19
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 17
- 238000006748 scratching Methods 0.000 description 15
- 230000002393 scratching effect Effects 0.000 description 15
- 108010058846 Ovalbumin Proteins 0.000 description 14
- -1 pH adjusters Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 239000006210 lotion Substances 0.000 description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- 206010020751 Hypersensitivity Diseases 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 208000026935 allergic disease Diseases 0.000 description 12
- 239000007928 intraperitoneal injection Substances 0.000 description 12
- 229940088594 vitamin Drugs 0.000 description 12
- 229930003231 vitamin Natural products 0.000 description 12
- 235000013343 vitamin Nutrition 0.000 description 12
- 239000011782 vitamin Substances 0.000 description 12
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000008363 phosphate buffer Substances 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- 238000007796 conventional method Methods 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 210000004681 ovum Anatomy 0.000 description 10
- 206010003645 Atopy Diseases 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
- 229920000053 polysorbate 80 Polymers 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241001474374 Blennius Species 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000002489 hematologic effect Effects 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 244000132059 Carica parviflora Species 0.000 description 4
- 235000014653 Carica parviflora Nutrition 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010024438 Lichenification Diseases 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 208000030961 allergic reaction Diseases 0.000 description 4
- 230000037336 dry skin Effects 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 150000003408 sphingolipids Chemical class 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229920002055 compound 48/80 Polymers 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- XMVQWNRDPAAMJB-UHFFFAOYSA-N (+)-13-Cyclopent-2-enyl-tridecansaeure Natural products OC(=O)CCCCCCCCCCCCC1CCC=C1 XMVQWNRDPAAMJB-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- SRELFLQJDOTNLJ-HNNXBMFYSA-N (R)-hydnocarpic acid Chemical compound OC(=O)CCCCCCCCCC[C@@H]1CCC=C1 SRELFLQJDOTNLJ-HNNXBMFYSA-N 0.000 description 1
- XMVQWNRDPAAMJB-QGZVFWFLSA-N (S)-chaulmoogric acid Chemical compound OC(=O)CCCCCCCCCCCC[C@H]1CCC=C1 XMVQWNRDPAAMJB-QGZVFWFLSA-N 0.000 description 1
- FYFDQJRXFWGIBS-UHFFFAOYSA-N 1,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C([N+]([O-])=O)C=C1 FYFDQJRXFWGIBS-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- SCZVLDHREVKTSH-UHFFFAOYSA-N 4',5,7-trihydroxy-3'-methoxyflavone Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 SCZVLDHREVKTSH-UHFFFAOYSA-N 0.000 description 1
- HDNLORHOQSPONM-UHFFFAOYSA-N 5,5-dinitrocyclohexa-1,3-diene Chemical compound [O-][N+](=O)C1([N+]([O-])=O)CC=CC=C1 HDNLORHOQSPONM-UHFFFAOYSA-N 0.000 description 1
- ZYWKQKQEAVWKHD-ILBGXUMGSA-N 5,7-dihydroxy-2-[(2r,3r)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)CO)=C1 ZYWKQKQEAVWKHD-ILBGXUMGSA-N 0.000 description 1
- KMYJDVOGPCWOTR-UDJTZZNJSA-N 5,7-dihydroxy-2-[(2r,3r)-3-[4-hydroxy-3-[(z)-3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)prop-1-en-2-yl]-5-methoxyphenyl]-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chromen-4-one Chemical compound C1=C(O)C(OC)=CC(\C=C(/CO)C=2C(=C(OC)C=C(C=2)[C@@H]2[C@H](OC3=CC=C(C=C3O2)C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)CO)O)=C1 KMYJDVOGPCWOTR-UDJTZZNJSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- XADKGDBMULSEAC-UHFFFAOYSA-N Gorlic acid Natural products OC(=O)CCCCC=CCCCCCCC1CCC=C1 XADKGDBMULSEAC-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- SRELFLQJDOTNLJ-UHFFFAOYSA-N Hydnocarpic acid Natural products OC(=O)CCCCCCCCCCC1CCC=C1 SRELFLQJDOTNLJ-UHFFFAOYSA-N 0.000 description 1
- NMICSFNNFDNGEL-ZCYQVOJMSA-N Hydnocarpin Natural products C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC(=CC=C3O2)C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)CO)=C1 NMICSFNNFDNGEL-ZCYQVOJMSA-N 0.000 description 1
- KMYJDVOGPCWOTR-UHFFFAOYSA-N Hydnowightin Natural products C1=C(O)C(OC)=CC(C=C(CO)C=2C(=C(OC)C=C(C=2)C2C(OC3=CC=C(C=C3O2)C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)CO)O)=C1 KMYJDVOGPCWOTR-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037855 Rash erythematous Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241001533104 Tribulus terrestris Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- NTXXGPYGMQQSML-QZTJIDSGSA-N americanin A Natural products OC[C@H]1Oc2cc(C=CC=O)ccc2O[C@@H]1c3ccc(O)c(O)c3 NTXXGPYGMQQSML-QZTJIDSGSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000007215 black sesame Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- UOSZQIQUCYTISS-UHFFFAOYSA-N chrysoeriol Natural products C1=C(O)C(C)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 UOSZQIQUCYTISS-UHFFFAOYSA-N 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- XADKGDBMULSEAC-MMTGSJLXSA-N gorlic acid Chemical compound OC(=O)CCCC\C=C/CCCCCC[C@@H]1CCC=C1 XADKGDBMULSEAC-MMTGSJLXSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- ZYWKQKQEAVWKHD-UHFFFAOYSA-N hydnocarpin-D Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)CO)=C1 ZYWKQKQEAVWKHD-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000005813 organ abnormality Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 125000001232 pantothenyl group Chemical group C(CCNC([C@H](O)C(C)(C)CO)=O)(=O)* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical class [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- YFGAFXCSLUUJRG-WCCKRBBISA-M sodium;(2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCCN=C(N)N YFGAFXCSLUUJRG-WCCKRBBISA-M 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 239000010343 sopoongsan Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 생약 추출물을 이용한 알러지성 피부질환 예방 및 치료용 조성물에 관한 것으로서, 더욱 상세하게는 대풍자 추출물 또는 대풍자, 호마자, 백선피, 목별자 및 백질려 복합 추출물이 아토피성 피부염을 유발한 동물모델에서 긁힘 횟수가 탁월하게 감소되며, 관능시험에서도 아토피성 피부염 점수를 낮추는 효과가 있고, 아토피성 피부염의 발현에 따른 혈액 중 IgE와 IL4의 상승을 감소시키는 효과를 확인함으로써 알러지성 피부질환에 매우 유효한 생약 추출물 및 이의 용도에 관한 것이다. The present invention relates to a composition for the prevention and treatment of allergic skin diseases using herbal extracts, and more particularly, the animal of which macrophage extract or macrophage, spermatozoon, ringworm skin, shepherdum and baekryeok complex extract causes atopic dermatitis The number of scratches in the model is excellently reduced, and the sensory test has an effect of lowering the atopic dermatitis score, and it is very effective for allergic skin diseases by confirming the effect of reducing the elevation of IgE and IL4 in the blood according to the expression of atopic dermatitis. Effective herbal extracts and uses thereof.
생약 추출물, 알러지성 피부질환 Herbal Extract, Allergic Skin Disease
Description
본 발명은 생약 추출물을 이용한 피부질환 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing and treating skin diseases using herbal extracts.
알러지성 피부질환에는 과민증(anaphylaxis), 알러지성 비염(allergic rhinitis), 천식(athma), 아토피성 피부염(atopic dermatitis) 및 두드러기 (urticaria)가 있으며 그 유병율은 점점 증가하고 있다[Wuthrich B. Int. Arch. Allergy Appl. Immunol., 90, pp3-10, 1989]. 일반적으로 알러지성 질환은 IgE에 의해 매개되며, 이는 Type 2 헬퍼 T 세포(Th2), 비만세포 및 호산구 (eosinophil) 등이 관여한다. Allergic skin diseases include anaphylaxis, allergic rhinitis, asthma, atopic dermatitis and urticaria, and the prevalence is increasing [Wuthrich B. Int. Arch. Allergy Appl. Immunol ., 90, pp 3-10, 1989]. Generally allergic diseases are mediated by IgE, which involves
알러지 반응의 작용기전은 제1형부터 제4형까지의 네 가지로 나누며, 제1형을 즉시형이라고 하고 제4형을 지연형이라고 한다. 아토피성 피부염은 그 중 제1형과 제4형의 알러지 반응이 관여하는 피부염이라고 생각하고 있다[일본 특허공보 2000-119127호]. 제1형 알러지는 주로 IgE 항체가 관여하며, 제4형은 항체 가 관여하지 않고 주로 각종 림프구, 특히 백혈구를 경유하는 염증반응이라고 알려져 있다. 아토피성 피부염은 알러지 반응으로 인한 질환으로 피부 건조화뿐만 아니라 표피과증식(hyperkeratosis), 홍반, 부종, 심한 소양증, 삼출과 부스럼 딱지를 특징으로 하고 급성기에는 표피 내에 수포를 형성하며 만성기에는 인성과 피부에 비후가 생기는 피부염증 등과 같은 여러 증상을 같이 수반하는 질환이다.The allergic reaction mechanism is divided into four types,
최근 수십 년간 선진국에서도 아토피성 질환의 이환율이 상당히 증가하는 추세에 있으며 우리나라에서도 최근 알러지성 질환의 급증과 함께 아토피성 피부염 환자가 증가하고 있다[Y. K. Tay, K. H. Konget al., J. Dermatology, 146, pp101-106, 2002]. 1980년에 아토피성 피부염을 비롯한 알러지 환자는 1% 미만이었으나, 2000년대에는 5% 이상으로 급증하고 있으며 잠재적인 환자까지 포함하면 10%가 넘는 것으로 추정되고 있다. 이러한 이유로는 산업과 문명의 발달로 인해 환경오염의 증가, 식생활의 변화, 스트레스의 가중 등이 거론되고 있다[R. Barnetson, M. Rogers., Br. Medicine J. 324, pp1376-1379, 2002].In the recent decades, the prevalence of atopic diseases has increased considerably in developed countries, and in Korea, the number of patients with atopic dermatitis is increasing with the proliferation of allergic diseases [YK Tay, KH Kong et al., J. Dermatology , 146, pp 101-106, 2002. In 1980, less than 1% of allergic patients, including atopic dermatitis, increased to more than 5% in the 2000s and more than 10% of potential patients. For this reason, due to the development of industry and civilization, the increase of environmental pollution, the change of diet, and the stress of stress have been mentioned [R. Barnetson, M. Rogers., Br. Medicine J. 324, pp1376-1379, 2002].
아토피 피부염은 유전인자와 환경인자가 관여하여 발병하는 면역성질환이다. 아토피 피부염은 만성적으로 건조하며 소양감이 심하고 반복적으로 재발되며 각종 자극에 의해 쉽게 피부염이 유발된다. 많은 경우에는 1~2주 간격으로 반복적으로 악화되며 적절한 관리를 하지 않으면 삼출을 동반한 홍반성 발진의 아급성 병변, 가죽과 같이 두꺼워진 태선화의 만성병변으로 진행된다. 아토피 피부염의 병리학적(조직검사 소견) 검사에서 각각의 소견은 병변의 단계에 따라 다르지만 대체로 만성이 되면 표피가 두꺼워지고 여러 가지 면역반응에 관여하는 세포의 침 윤이 관찰된다. 특히, 면역 반응을 담당하는 비장 세포가 증가되어 있으며 비정상적으로 증가된 항원제시 능력을 가진다. 또한, 아토피 피부염에 의해 비만세포의 수는 증가되므로 탈과립상태를 나타낸다. 아토피 피부염 환자의 80~90%는 혈청 IgE가 증가되는데, 알러지성 비염이나 천식 같은 호흡기 아토피가 동반되어 있는 경우에는 특히 혈청 IgE가 높다. 약 87% 아토피 피부염 환자에서 피부반응검사 혹은 RAST(radioallergosorbent test) 검사에서 여러 가지 음식과 흡입 알레르겐에 대한 특이 IgE가 양성으로 관찰되어지며, 만약 혈청 IgE가 증가된 경우, 아토피 피부염과 같은 알러지성 질환일 가능성이 높은 것으로 진단된다. Atopic dermatitis is an immune disease caused by genetic and environmental factors. Atopic dermatitis is chronically dry, has a strong pruritus, recurs repeatedly, and dermatitis is easily induced by various stimuli. In many cases, the disease deteriorates repeatedly at intervals of 1 to 2 weeks, and if not properly managed, it progresses to subacute lesions of erythematous rashes with exudates and chronic lesions of thickened lichenitis, such as leather. In pathological (histochemical) findings of atopic dermatitis, the findings vary depending on the stage of the lesion. However, when chronic, the epidermis thickens and cells involve in various immune responses. In particular, spleen cells responsible for the immune response are increased and have an abnormally increased antigen presenting ability. In addition, the number of mast cells is increased by atopic dermatitis, indicating a degranulation state. Eighty to 90% of patients with atopic dermatitis have elevated serum IgE, especially if they are accompanied by respiratory atopy such as allergic rhinitis or asthma. In approximately 87% of patients with atopic dermatitis, skin tests or radioallergosorbent tests (RAST) test show positive IgE for various foods and inhaled allergens.If serum IgE is elevated, allergic diseases such as atopic dermatitis Is diagnosed as likely.
한방에서는 아토피 피부염은 내선, 태선(胎癬), 태창(胎瘡), 습창(濕瘡) 등의 범주에서 살펴볼 수 있으며, 특히 유아형의 경우 태열(胎熱)에 속한다[김미정, 이승연. 대한소아과학회지, 14, pp169-184, 2000; 박민철 외, 대한안이비인후피부과학회지, 15, pp226-252, 2002; 백종현 외, 대한피부과학회지, 37, pp1553-1559, 1999]. 이러한 원인에는 풍열(風熱), 혈열(血熱), 혈허(血虛) 및 비(脾), 위(胃)의 운화(運化)기능의 실조에 의한 태화습열(胎火濕熱), 풍습열(風濕熱)의 침입 등을 들 수 있으며, 이외에도 기온의 변화, 음식물, 불규칙한 수유 습관, 의복 마찰, 한냉(寒冷)의 변화 등의 자극이 관여된다[趙純修. 중의피부병학. 과학출판사. pp110-112, 1999; 顧伯華. 실용중의외과학. 상해과학기술출판사. pp460-464, 1996]. In oriental medicine, atopic dermatitis can be found in the categories of exten- sion, Taesun (태), Taechang (胎 瘡), and wet swelling (특히), especially in the case of infantile type (Kim Mi-jeong, Lee Seung-yeon. Korean Journal of Pediatric Science , 14, pp169-184, 2000; Park, Min-Chul et al., Korean Journal of Ophthalmology and Otolaryngology and Dermatology, 15, pp226-252, 2002; Baek, Jong-Hyun et al., The Korean Dermatological Society , 37, pp1553-1559, 1999]. Such causes include wind fever, blood fever, blood debris, rain, and gastrointestinal fever due to ataxia of malformation. Heat invasion and the like, in addition to stimulation such as changes in temperature, food, irregular feeding habits, clothing friction, changes in cold and cold [趙 純 修. Middle Dermatology . Science publisher. pp 110-112, 1999;顧伯華. Practical Surgery . Shanghai Science and Technology Press. pp 460-464, 1996.
최근에 상기와 같은 여러 종류의 알러지성 질환의 증가로 이에 대한 연구가 활발히 진행되어 급진적인 면역학의 발전으로 알러지성 질환의 구명 및 치료에 많 은 진보가 있었음에도 불구하고, 아직까지 충분히 알러지성 질환을 치료할 수 있는 약물의 개발이 이루어져 있지 않다. 현재까지 아토피 피부염에는 면역요법과 약물요법의 치료가 시행되고 있으나 특별한 치료제가 없어, 증상이 심한 경우 스테로이드제제(부신피질 호르몬제)를 사용하였으나 단기간의 임상 증상 완화에만 효과가 있고 다시 수일 내에 증상이 유발되는 정도의 효과가 대부분이다. 스테로이드제제의 국소적 투여가 장기간 계속되면 부신 기능의 저하를 초래하여 여러 가지 부신피질호르몬제에 의한 부작용이 나타나게 되어 계속적으로 사용하기에 부적절한 치료방법이다. 아토피성 피부염 환자를 위한 적절한 치료제가 없으므로 많은 경우에서 체질개선과 민간요법, 한방치료에 의존하여 임상증상의 완화와 치료효과를 기대하나 아직까지 장기적으로 부작용이 없이 사용할 수 있는 치료제가 개발되지 못하고 있는 실정이다.In recent years, the research has been actively conducted due to the increase in allergic diseases as described above. Despite the advances in radical immunology, there have been many advances in the lifesaving and treatment of allergic diseases. There is no development of drugs that can cure. To date, atopic dermatitis has been treated with immunotherapy and pharmacotherapy, but there are no special treatments. In case of severe symptoms, steroids (adrenal corticosteroids) were used. Most of the effects are induced. Long-term topical administration of steroids leads to a decrease in adrenal function, resulting in side effects caused by various corticosteroids, which is inappropriate for continued use. As there is no appropriate treatment for patients with atopic dermatitis, in many cases relying on constitution improvement, folk remedies and oriental medical treatment, we expect to alleviate the clinical symptoms and cure, but there are no treatments that can be used without long-term side effects. It is true.
최근 천연물을 이용한 알러지 또는 아토피 피부염의 치료를 위한 많은 연구가 이루어져 있는데, 대한민국 공개특허 제2004-97026호에는 각종 천연물을 이용한 아토피성 피부염 예방 및 치료에 관한 조성물이 알려져 있으며, 대한민국 공개특허 제2005-9172호에도 역시 아토피성 피부질환 환자의 체질개선 조성물이 설시되어 있고, 대한민국 공개특허 제2004-86790호에는 흑미 추출물을 이용한 알러지성 질환 치료 및 예방 조성물에 관하여 설시되어 있으며, 대한민국 공개특허 제2005-22586호에는 질경이 추출물을 이용한 아토피성 피부염 치료제가 알려져 있다. 또한, 대한민국 공개특허 제2004-18118호에는 식품의약품안전청의 식품원료 분류표에서 식물성 원료 중의 하나인 다래 추출물을 이용한 알러지성 질환 치료용 조성물이 공 개되어 있으며, 식품으로서 사용이 가능한 소엽 추출물을 이용한 알러지성 질환 치료용 조성물도 공개되어 있다[대한민국 공개특허 제2002-61963호]. 더 나아가 일본 특허공보 2000-119127호에는 상백피 추출물, 황금 추출물 및 살리실산 중에서 선택된 어느 하나 이상이 피부염 등을 예방 또는 치료할 수 있다고 설시되어 있다. 이외에도 천연물을 이용한 아토피 피부염과 관련되어 약리학적 연구가 많이 보고되어 있는데, 특히 소풍산(消風散)이 흰쥐의 히스티민 유리 억제와 림포카인 조절에 영향을 미친다고 알려져 있으며[박성남. 소풍산이 BALB/c Mouse를 이용한 Atopy 피부염 Model에 미치는 영향. 경희대학교 대학원 박사학위논문, 2002], 상백피(桑白皮)가 화합물 48/80에 의해 유도된 과민성 쇼크과 비만세포의 히스타민 유리와 탈과립을 억제한다고 알려져 있다[김정수, 전병득. 상백피가 백서 장간막 비만세포에 미치는 영향. 전북의대 논문집, 10, pp231-239, 1986; 전병득, 송창호, 최영숙, 박병건, 이무삼. 상백피가 화합물 48/80에 의하여 유도된 과민성 쇼크와 비만세포의 히스타민 유리에 미치는 영향. 대한해부학회지, 24, pp193-203, 1991]. Recently, many studies for the treatment of allergic or atopic dermatitis using natural products have been made, and Korean Patent Publication No. 2004-97026 discloses a composition for preventing and treating atopic dermatitis using various natural products. 9172 also describes a constitution improvement composition of patients with atopic skin disease, and Korean Patent Laid-Open No. 2004-86790 discloses a treatment and prevention composition for allergic diseases using black rice extract, and Korea Patent Publication No. 2005-86 In 22586, atopic dermatitis treatment using a plantain extract is known. In addition, the Republic of Korea Patent Publication No. 2004-18118 discloses a composition for treating allergic diseases using the Darae extract which is one of the vegetable raw materials in the food raw material classification table of the Korea Food and Drug Administration, using the leaflet extract that can be used as food A composition for treating allergic diseases is also disclosed (Korean Patent Publication No. 2002-61963). Furthermore, Japanese Patent Application Laid-Open No. 2000-119127 describes that any one or more selected from lettuce extract, golden extract and salicylic acid can prevent or treat dermatitis. In addition, many pharmacological studies have been reported in relation to atopic dermatitis using natural products. Especially, it is known that Sopoong-san (영향 風 散) influences histamine release and lymphokine regulation in rats. Effect of Sopung Acid on Atopy Dermatitis Model using BALB / c Mouse. Kyung Hee University Graduate School, Ph.D. , 2002], Sangbaekpi is known to inhibit histamine release and degranulation of hypersensitivity shock and mast cells induced by Compound 48/80 [Kim, Jung-Su, Jeon, Byung-Deuk. Effect of Epithelium on Mesenteric Mast Cells in Rats. Jeonbuk Medical College , 10, pp231-239, 1986; Jeon Byung Deuk, Song Chang Ho, Young Sook Choi, Byeong Gun Park, and Moo Sam Lee. Effect of Epidermis on Sensitization Shock and Histamine Release of Mast Cells Induced by Compound 48/80. Journal of the Korean Society of Anatomy , 24, pp193-203, 1991].
천연물을 이용한 많은 연구나 특허가 공개되어 있지만 지금까지 본 발명에서 사용한 생약 추출물을 이용한 알러지성 피부염 등을 치료 또는 예방할 수 있는 의약품, 화장품 또는 식품 등에 대하여는 전혀 알려진 바가 없다. Although many studies and patents using natural products have been published, there is no known drug, cosmetics, or foods that can treat or prevent allergic dermatitis using the herbal extract used in the present invention.
이에, 본 발명자들은 알러지성 피부 질환에 효능이 있는 생약들을 선별하였고, 대풍자 추출물 또는 대풍자, 호마자, 백선피, 목별자 및 백질려의 추출물을 복합 처방함으로써 상승 효과를 발휘하여 알러지성 피부 질환에 매우 유효한 것을 확인함으로써 본 발명을 완성하게 되었다.Accordingly, the present inventors selected herbal medicines that are effective in allergic skin diseases, and have a synergistic effect by prescribing a combination of extracts of Pung Pung or extracts of Pung Pung, Hojaja, ringworm, pastoral and white Jill to allergic skin diseases. The present invention has been completed by confirming that it is very effective.
따라서, 본 발명의 목적은 대풍자 추출물 또는 대풍자, 호마자, 백선피, 목별자 및 백질려 복합 추출물을 포함하는 알러지성 피부질환 예방 및 치료용 조성물, 건강보조식품 및 화장료를 제공하는데 있다.Accordingly, it is an object of the present invention to provide a composition for preventing and treating allergic skin diseases, health supplements, and cosmetics, including the extract of saengpunggi or saengpung, yamja, ringworm skin, woodpecker and baekryeok complex.
본 발명은 대풍자 추출물 또는 대풍자, 호마자, 백선피, 목별자 및 백질려 복합 추출물을 포함하는 알러지성 피부질환 예방 및 치료용 조성물, 건강보조식품 및 화장료를 그 특징으로 한다.The present invention is characterized by a composition for preventing and treating allergic skin diseases, including a saengpung extract or a saengpung, yamja, ringworm skin, woodpecker and baekryeok complex extracts, health supplements and cosmetics.
본 발명의 생약 추출물을 포함하는 조성물은, 난자 알부민(Ovum albumin)과 수산화알루미늄(Aluminium hydroxide)을 복강 내 주사하고 포스페이트 버퍼 패취 처리하여 아토피성 피부염을 유발한 BALB/C 생쥐와 1-클로로-2,4-디니트로벤젠을 처리하여 아토피성 피부염을 유발한 NC/Nga 생쥐에서 긁힘 횟수를 탁월히 억제하며, 관능평가시험에서도 아토피성 피부염 점수를 낮추는 효과가 있었고, 아토피성피부염의 발현에 따른 혈액 중 IgE와 IL4의 상승을 감소시키는 효과를 나타냄으로 알러지성 피부질환 예방 및 치료용 조성물, 건강보조식품 및 화장료로 유용하게 활용될 수 있다. The composition comprising the herbal extract of the present invention, BALB / C mice and a 1-chloro-2 that induced atopic dermatitis by intraperitoneal injection of egg albumin (Avum albumin) and aluminum hydroxide (Aluminium hydroxide) and treated with phosphate buffer patch In the NC / Nga mice that induced atopic dermatitis by treatment with 4,4-dinitrobenzene, the number of scratches was remarkably suppressed, and in the sensory evaluation test, the atopic dermatitis score was also lowered. By showing the effect of reducing the elevation of IgE and IL4 can be useful as a composition for preventing and treating allergic skin diseases, dietary supplements and cosmetics.
이와 같은 본 발명을 더욱 상세하게 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.
본 발명은 대풍자 추출물 또는 대풍자, 호마자, 백선피, 목별자 및 백질려 복합 추출물이 아토피성 피부염을 유발한 동물모델에서 긁힘 횟수가 탁월하게 감소되며, 관능시험에서도 아토피성 피부염 점수를 낮추는 효과가 있고, 아토피성 피부염의 발현에 따른 혈액 중 IgE와 IL4의 상승을 감소시키는 효과를 확인함으로써 알러지성 피부질환에 매우 유효한 생약 복합 추출물 및 이의 용도에 관한 것이다. In the present invention, the number of scratches is greatly reduced in the animal model in which the saengpung extract or the saengpung, yamja, ringworm skin, woodpecker and white zirconia complex induced atopic dermatitis, and the sensory test has an effect of lowering the atopic dermatitis score. In addition, the present invention relates to a highly effective herbal extract and its use for allergic skin diseases by confirming the effect of reducing the elevation of IgE and IL4 in the blood according to the expression of atopic dermatitis.
먼저, 본 발명에 따른 조성물의 각 성분에 해당되는 생약성분에 대해 알아보면 다음과 같다.First, looking at the herbal ingredients corresponding to each component of the composition according to the present invention.
대풍자(Hydnocarpi semen)는 대풍자 나무 또는 동속근연식물의 씨로서, 길이 2~3 cm, 지름 1~2 cm의 오갈색 둔한 능형이고, 딱딱한 종피를 제거하면 기름이 많은 암갈색 내배유가 있고, 지금까지 확인된 주성분은 하이드노카르픽산(hydnocarpic acid), 카울무그릭산(chaulmoogric acid) 및 고르릭산(gorlic acid)을 함유하고 있는 대풍자유와 하이드노카르핀(hydnocarpin), 메톡시하이드노카르핀(methoxyhydnocarpin), 하이드노이틴(hydnowightin), 네오하이드노카르핀(neohydnocarpin)과 같은 플라볼리그난(flavolignan)과 아피게닌(apigenin), 루테올린(luteolin), 크리소에리올(chrysoeriol)과 같은 플라보노이드이다. Hydnocarpi semen is a seed of sapling tree or homologous root plant. It is a brownish-brown dull ridge of 2 ~ 3 cm in length and 1 ~ 2 cm in diameter, and the oily dark brown endosperm is removed until the hard seed is removed. The main components of this formula are Dungpoong Free, Hydnocarpin, and methoxyhydnocarpin, which contain hydnocarpic acid, chaulmoogric acid, and gorlic acid. And flavonoids such as flavognan and apigenin, luteolin, and chrysoeriol, such as hydnowightin and neoohydnocarpin.
대풍자를 물, 메탄올, 에탄올 및 부탄올 중에서 선택된 1종 이상의 용매로 추출하여 대풍자 추출물을 제조하고, 이 추출물이 아토피와 같은 알러지성 피부질환에 탁월한 효과를 보였다. Extraction of the macrophages with one or more solvents selected from water, methanol, ethanol and butanol to prepare the macrosporum extract, and the extract showed an excellent effect on allergic skin diseases such as atopy.
호마자는 검은깨로 알려져 있으며, 자양강장, 점활, 해독, 병후변비, 부스럼 효능이 알려져 있다. Khojaja is known as black sesame, nourishing tonic, viscous, detoxification, constipation, swelling effect is known.
백선피는 백선의 근피를 말하며, 간헌열, 두통, 월경장애, 류마티스, 황달, 해열 등의 치료 효능이 알려져 있다. Ringworm refers to the dermis of ringworm, and is known for its therapeutic efficacy, such as hepatic degeneration, headache, menstrual disorders, rheumatism, jaundice, and fever.
목별자(Momordicae Semen)는 중국남부지방에 널리 분포하는 다년생의 넝쿨성 식물인 목별의 성숙한 종자로서 9 ~ 11월경에 과실을 채취하여 두 쪽으로 잘라서 반쯤 말랐을 때 종자를 빼내거나 항아리에 넣어서 과피가 부패되었을 때 종자를 분리하여 사용한다. 이러한 목별자는 소염작용이 강하고 류마치스성 동통 및 근경련 등에 효과가 있는 것으로 알려져 있다. Momordicae Semen is a mature herbaceous, perennial vine, widely distributed in southern China, harvesting fruit from September to November, cutting it in two, cutting it in half, and removing the seeds or putting them in a jar to rot the skin. Separate the seeds when used. These pastors are known to have strong anti-inflammatory effects and are effective in rheumatoid pain and muscle spasms.
백질려(Tribulus terrestris L.)는 남가새과(Zygophyllaseae) 식물로서 백질려 열매는 고혈압, 중풍에 효과가 있는 것으로 알려져 있다. Tribulus terrestris L. is a Zygophyllaseae plant and its fruits are known to be effective in hypertension and stroke.
상기 대풍자, 호마자, 백선피, 목별자 및 백질려를 최적의 혼합비로 혼합 후, 물, 메탄올, 에탄올 및 부탄올 중에서 선택된 1종 이상의 용매로 추출하여 생약 복합 추출물을 제조하고, 이 추출물이 아토피와 같은 알러지성 피부질환에 탁월한 효과를 보였다. 상기 최적의 혼합비는 대풍자, 호마자, 백선피, 목별자 및 백질려가 1 : 0.1 ~ 1.0 : 0.01 ~ 0.5 : 0.01 ~ 0.5 : 0.01 ~ 0.5의 중량비이다. 더욱 바람직하게는 1 : 0.3 ~ 0.7 : 0.05 ~ 0.3 : 0.05 ~ 0.3 : 0.05 ~ 0.3이다. 상기 범위를 벗어나면 원하는 효과가 발현되지 않으며, 과다 사용하면 부작용이 발생할 수 있다.After mixing the saengpungja, Homaja, ringworm skin, woodpecker and white Zhijiri at the optimum mixing ratio, and extracted with one or more solvents selected from water, methanol, ethanol and butanol to prepare a herbal extract extract, the extract is atopy and The same effect was shown for allergic skin diseases. The optimum mixing ratio is the weight ratio of the saenggija, Hojaja, ringworm skin, woodpecker and white jilchi 1: 0.1 ~ 1.0: 0.01 ~ 0.5: 0.01 ~ 0.5: 0.01 ~ 0.5. More preferably, it is 1: 0.3-0.7: 0.05-0.3: 0.05-0.3: 0.05-0.3. If it is out of the above range, the desired effect is not expressed, and when used excessively, side effects may occur.
또한, 상기 복합 추출물(5종) 제조 시 생약 혼합 과정에서 고삼(Sophora flavcscens)을 대풍자 1 중량부에 대하여 0.01 ~ 0.5 중량부, 바람직하게는 0.05 ~ 0.3 추가로 추출하여도 아토피와 같은 알러지성 피부질환에 탁월한 효과를 보였다. 또한, 상기 복합 추출물(6종, 고삼 포함) 제조시 생약 혼합 과정에서 대풍자 1 중량부에 대하여 창이자(도꼬마리) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부), 우방자(우엉씨) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부), 만형자(萬荊子) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부), 감국(甘菊) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부), 백하수오(白何首烏) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부), 형개(荊芥) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부), 위령선(威靈仙) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부), 박하(薄荷) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부), 용뇌(龍腦) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부), 석우황(石牛黃) 0.001 ~ 0.3 중량부(더욱 바람직하게는 0.01 ~ 0.15 중량부), 석창포(石菖蒲) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부), 전충 0.001 ~ 0.3 중량부(더욱 바람직하게는 0.01 ~ 0.15 중량부) 및 감초(甘草) 0.01 ~ 0.5 중량부(더욱 바람직하게는 0.05 ~ 0.3 중량부)를 추가로 추출하여도 그 효능이 확인되었다. In addition, allergic skin such as atopic dermatitis may be extracted by extracting 0.01 to 0.5 parts by weight, preferably 0.05 to 0.3, based on 1 part by weight of saengpung ( Sophora flavcscens ) during the mixing of herbal medicines during the preparation of the complex extract (five species). Excellent effect on the disease. In addition, 0.01 to 0.5 parts by weight (more preferably 0.05 to 0.3 parts by weight) of Changgiza (dokkari), 1 part by weight of the saengpung in the process of mixing the herbal medicine during the preparation of the complex extract (including 6 kinds, goose ginseng), allium (burdock seed) 0.01 to 0.5 parts by weight (more preferably 0.05 to 0.3 parts by weight), man-shaped 0.01 to 0.5 parts by weight (more preferably 0.05 to 0.3 parts by weight), and gakguk 0.01 to 0.5 parts by weight Parts (more preferably 0.05 to 0.3 parts by weight), Baek Shou (0.01 to 0.5 parts by weight) (more preferably 0.05 to 0.3 parts by weight), mold opening (0.01 to 0.5 parts by weight) (more preferably 0.05 to 0.3 parts by weight), lieutenant line 0.01 to 0.5 parts by weight (more preferably 0.05 to 0.3 parts by weight), peppermint 0.01 to 0.5 parts by weight (more preferably 0.05 to 0.3 parts by weight) , 0.01-0.5 parts by weight (more preferably 0.05-0.3 parts by weight), 0.001-0.3 parts by weight (more preferably 0. 01 to 0.15 parts by weight), 0.01 to 0.5 parts by weight (more preferably 0.05 to 0.3 parts by weight), stoneworm 0.001 to 0.3 parts by weight (more preferably 0.01 to 0.15 parts by weight) and licorice (甘草) ) The efficacy was also confirmed by further extracting 0.01 to 0.5 parts by weight (more preferably, 0.05 to 0.3 parts by weight).
한편, 본 발명의 생약 복합 추출물은 상기와 같이 각각의 생약재를 혼합 후 추출할 수도 있고, 각각의 생약재 추출물을 얻은 후 혼합할 수도 있다.Meanwhile, the herbal extract of the present invention may be extracted after mixing the respective herbal medicines as described above, or may be mixed after obtaining the respective herbal medicine extracts.
본 발명의 대풍자 추출물 또는 상기 생약 복합 추출물의 아토피성 피부염에 대한 효능을 확인하기 위하여 BALB/C 생쥐에게 난자 알부민과 수산화알루미늄을 복강 내 주사하고 포스페이트 버퍼 패취를 부착하여 아토피성 피부염을 유발하고, 유전적으로 아토피성 피부질환 소인을 가진 NC/Nga 생쥐에게 1-클로로-2,4-디니트로 벤젠을 처리하여 아토피성 피부염을 유발하여 긁힘 횟수(scratching frequency), 관능 평가방법 및 혈액 중 IgE와 IL4 발현량의 검색을 실시하였다.In order to confirm the efficacy on the atopic dermatitis of the saengsugung extract or the herbal extract of the present invention intraperitoneally injected BALB / C mice with egg albumin and aluminum hydroxide and attach a phosphate buffer patch to induce atopic dermatitis, NC-Nga mice with predisposition to atopic dermatological diseases treated with 1-chloro-2,4-dinitrobenzene to induce atopic dermatitis, the frequency of scratching, sensory evaluation and expression of IgE and IL4 in the blood The amount was searched.
그 결과, 생약 복합 추출물은 난자 알부민과 수산화알루미늄을 복강 내 주사하고 포스페이트 버퍼 패취를 부착하여 아토피성 피부염을 유발한 BALB/C 생쥐에서 투여기간에 비례하여 긁힘 횟수(scratching frequency)를 유의성 있게 감소시켰고, 아토피성 피부질환 정도를 나타내는 아토피성 피부질환 지수 역시 투여기간에 비례하여 감소시켰으며, 혈액 중 IgE와 IL4 발현량 역시 유의성 있게 감소시켰다. 또한, 아토피성 피부질환 소인을 가진 NC/Nga 생쥐에게 1-클로로-2,4-디니트로벤젠을 처리하여 아토피성 피부염을 유발한 실험동물에서도 투여기간에 비례하여 긁힘 횟수(scratching frequency)를 유의성 있게 감소시켰고, 아토피성 피부질환 정도를 나타내는 아토피성 피부질환 지수 역시 투여기간에 비례하여 감소시켰으며, 혈액 중 IgE와 IL4 발현량 역시 유의성있게 감소시켰다. As a result, the herbal extracts were injected intraperitoneally with egg albumin and aluminum hydroxide and attached with phosphate buffer patch to significantly reduce the scratching frequency in proportion to the duration of administration in BALB / C mice that induced atopic dermatitis. In addition, the atopic dermatitis index, which indicates the degree of atopic dermatitis, was also decreased in proportion to the duration of administration, and the expression of IgE and IL4 in the blood was also significantly decreased. In addition, the frequency of the scratching frequency was significantly proportional to the administration period in the experimental animals that induced atopic dermatitis by treating 1 / chloro-2,4-dinitrobenzene in NC / Nga mice with atopic dermatitis predisposition. In addition, the atopic dermatitis index, which indicates the degree of atopic dermatitis, was also decreased in proportion to the duration of administration, and the expression of IgE and IL4 in the blood was also significantly decreased.
따라서, 본 발명은 대풍자 추출물 또는 상기에서 얻어지는 생약 복합 추출물을 포함하는 알러지성 피부질환 예방 및 치료용 조성물을 제공한다. 상기 알러지성 피부질환은 알러지성 피부염, 아토피 피부염, 접촉성 피부염, 피부과민증, 곤충 알러지, 식품 알러지 또는 약품 알러지이다.Accordingly, the present invention provides a composition for the prevention and treatment of allergic skin diseases comprising the saengpung extract or the herbal extract obtained above. The allergic skin disease is allergic dermatitis, atopic dermatitis, contact dermatitis, skin hypersensitivity, insect allergy, food allergy or drug allergy.
본 발명의 알러지성 피부질환 예방 및 치료를 위한 조성물은, 조성물 총 중량에 대하여 상기 대풍자 추출물 또는 상기 생약 복합 추출물을 0.02 ~ 50 중량%로 포함하는 것이 바람직하다. The composition for the prevention and treatment of allergic skin diseases of the present invention, it is preferable that the total saenggi extract or the herbal extracts in an amount of 0.02 to 50% by weight based on the total weight of the composition.
본 발명의 추출물을 포함하는 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The composition comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명의 추출물의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다. The pharmaceutical dosage forms of the extracts of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.
본 발명에 따른 추출물을 포함하는 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제(연고제, 패취제 등), 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라 핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Compositions comprising the extracts according to the invention are oral formulations, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations (ointments, patches, etc.), suppositories, and sterilization, respectively, according to conventional methods. It can be formulated and used in the form of injectable solutions. Examples of carriers, excipients and diluents that can be included in the composition containing the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid form may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients may be included, such as wetting agents, sweeteners, fragrances, and preservatives. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
뿐만 아니라 본 발명의 조성물은 상기 추출물을 필수 구성요소로 하고 피부에 이미 유익하다고 알려져 있는 통상의 물질도 포함할 수 있다. 예를 들면, 비타민 C나 비타민 E, 필수지방산 등을 포함할 수 있다.In addition, the composition of the present invention may include a conventional substance which is known to be beneficial to the skin and the extract as an essential component. For example, it may include vitamin C, vitamin E, essential fatty acids and the like.
본 발명의 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 조성물은 1일 0.1 ~ 500 mg/kg으로, 바람직하게는 1 ~ 200 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the composition of the present invention is preferably administered at 0.1 to 500 mg / kg, preferably 1 to 200 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관 내(Intracerebroventricular) 주사에 의해 투여될 수 있다. The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or Intracerebroventricular injection.
또한, 본 발명은 대풍자 추출물 또는 상기에서 얻어지는 생약 복합 추출물(5종, 6종 또는 19종)을 포함하는 피부질환 예방 및 개선용 조성물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강보조식품을 제공한다.In addition, the present invention provides a dietary supplement comprising a composition for preventing and improving skin diseases, including a saengpung saeng extract or herbal extracts (5 species, 6 species or 19 species) obtained from the above, and a food supplement acceptable food additive. to provide.
본 조성물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 껌, 차, 비타민 복합제, 건강 기능성 식품류, 분말, 과립, 정제, 캡슐 또는 음료 등이 있다.Examples of the food to which the present composition can be added include various foods, gums, teas, vitamin complexes, health functional foods, powders, granules, tablets, capsules, and beverages.
또한, 알러지성 피부염 치료 및 예방을 목적으로 식품 또는 음료에 첨가될 수 있다. 이때, 식품 또는 음료 중의 상기 조성물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. It may also be added to foods or beverages for the purpose of treating and preventing allergic dermatitis. At this time, the amount of the composition in the food or beverage may be added in 0.01 to 15% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml. have.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 조성물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the composition as an essential ingredient in the indicated ratios, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 건강보조식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강보조식품들은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 전체 건강보조식품 100 중량부당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the dietary supplement of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavoring agents, colorants and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid And salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the health supplements of the present invention may contain a flesh for preparing natural fruit juices and fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the total dietary supplement of the present invention.
또한, 본 발명은 대풍자 추출물 또는 상기 제조공정에서 얻어지는 생약 복합 추출물(5종, 6종 또는 19종)을 포함하는 피부질환 예방 및 개선용 화장료를 제공한다.In addition, the present invention provides a cosmetic for preventing and improving skin diseases, including the saengpung extract or herbal extracts (5, 6 or 19 species) obtained in the manufacturing process.
본 화장료에 첨가할 수 있는 제품으로는, 예를 들어, 각종 크림, 로션, 스킨 등과 같은 화장품류와 클렌징, 세안제, 비누, 트리트먼트, 미용액 등이 있다.Examples of products that can be added to the cosmetics include cosmetics such as various creams, lotions, skins, and the like, and cleansing agents, face washes, soaps, treatments, and essences.
본 발명의 화장료는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 조성물을 포함한다.Cosmetics of the present invention comprises a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.
수용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 B1, 비타민 B2, 비타민 B6, 피리독신, 염산피리독신, 비타민 B12, 판토텐산, 니코틴산, 니코틴산아미드, 엽산, 비타민 C, 비타민 H 등을 들 수 있으며, 그들의 염(티아민염산염, 아스코르빈산나트륨염 등)이나 유도체(아 스코르빈산-2-인산나트륨염, 아스코르빈산-2-인산마그네슘염 등)도 본 발명에서 사용할 수 있는 수용성 비타민에 포함된다. 수용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 수득할 수 있다.The water-soluble vitamin may be any compound that can be incorporated into cosmetics, but preferably vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, vitamin H, and the like. The salts thereof (thiamine hydrochloride, sodium ascorbate salt, etc.) or derivatives (ascorbic acid-2-sodium phosphate salt, ascorbic acid-2-magnesium phosphate salt, etc.) can also be used in the present invention. Included in The water-soluble vitamins can be obtained by conventional methods such as microbial transformation, purification from microorganism culture, enzyme or chemical synthesis.
유용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 A, 카로틴, 비타민 D2, 비타민 D3, 비타민 E (DL-알파 토코페롤, D-알파 토코페롤, d-알파 토코페롤) 등을 들 수 있으며, 그들의 유도체 (팔미틴산아스코르빈, 스테아르산아스코르빈, 디팔미틴산아스코르빈, 아세트산 DL-알파 토코페롤, 니코틴산 DL-알파 토코페롤, 비타민 E, DL-판토테닐알코올, D-판토테닐알코올, 판토테닐에틸에테르 등) 등도 본 발명에서 사용되는 유용성 비타민에 포함된다. 유용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소 또는 화학 합성법 등의 통상의 방법에 의해 취득할 수 있다.The oil-soluble vitamin may be any compound that can be incorporated into cosmetics, but preferably vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (DL-alpha tocopherol, D-alpha tocopherol, d-alpha tocopherol), and the like. , Derivatives thereof (ascorbic palmitate, ascorbic stearate, ascorbic acid dipalmitate, DL-alpha tocopherol acetate, DL-alpha tocopherol nicotinic acid, vitamin E, DL-pantothenyl alcohol, D-pantothenyl alcohol, pantothenyl) Ethyl ether) and the like are also included in the oil-soluble vitamins used in the present invention. Oil-soluble vitamins can be obtained by conventional methods such as microbial transformation, purification of microorganism culture, enzyme or chemical synthesis.
고분자 펩티드로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 콜라겐, 가수 분해 콜라겐, 젤라틴, 엘라스틴, 가수 분해 엘라스틴, 케라틴 등을 들 수 있다. 고분자 펩티드는 미생물의 배양액으로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 정제 취득할 수 있으며, 또는 통상 돼지나 소 등의 진피, 누에의 견섬유 등의 천연물로부터 정제하여 사용할 수 있다.The polymer peptide may be any compound as long as it can be incorporated into cosmetics. Preferably, collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin, and the like can be given. Polymeric peptides can be purified and obtained by conventional methods such as purification from microbial cultures, enzymatic methods or chemical synthesis methods, or can be purified and used from natural products such as dermis and pig silk such as pigs and cattle.
고분자 다당으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 히드록시에틸셀룰로오스, 크산탄검, 히알루론산나트륨, 콘드로이 틴 황산 또는 그 염(나트륨염 등) 등을 들 수 있다. 예를 들어, 콘드로이틴 황산 또는 그 염 등은 통상 포유동물이나 어류로부터 정제하여 사용할 수 있다.The polymer polysaccharide may be any compound as long as it can be incorporated into cosmetics. Preferably, hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or a salt thereof (sodium salt, etc.) may be mentioned. For example, chondroitin sulfate or its salt, etc. can be normally purified from a mammal or fish.
스핑고 지질로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 세라미드, 피토스핑고신, 스핑고당지질 등을 들 수 있다. 스핑고 지질은 통상 포유류, 어류, 패류, 효모 또는 식물 등으로부터 통상의 방법에 의해 정제하거나 화학 합성법에 의해 취득할 수 있다.The sphingolipid may be any compound as long as it can be blended into cosmetics. Preferably, ceramide, phytosphingosine, sphingosaccharide lipid, etc. may be mentioned. Sphingo lipids can usually be purified from mammals, fish, shellfish, yeasts or plants by conventional methods or obtained by chemical synthesis.
해초 엑기스로는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 갈조 엑기스, 홍조 엑기스, 녹조 엑기스 등을 들 수 있으며, 또한 이들의 해초 엑기스로부터 정제된 칼라기난, 아르긴산, 아르긴산나트륨, 아르긴산칼륨 등도 본 발명에서 사용되는 해초 엑기스에 포함된다. 해초 엑기스는 해초로부터 통상의 방법에 의해 정제하여 취득할 수 있다.The seaweed extract may be any compound as long as it can be blended into cosmetics, but preferably, brown algae extract, red algae extract, green algae extract, and the like, and calginane, arginic acid, sodium arginate and argin purified from these seaweed extracts Potassium ginate and the like are also included in the seaweed extract used in the present invention. Seaweed extract can be obtained by purification from seaweed by conventional methods.
본 발명의 화장료에는 상기 필수 성분과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합해도 된다.In addition to the said essential component, you may mix | blend the cosmetics of this invention with the other components normally mix | blended with cosmetics as needed.
이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.Other components that may be added include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, Blood circulation accelerators, cooling agents, restriction agents, purified water and the like.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하지만, 총 중량에 대하여 바람직하게는 0.01 ~ 5 중량%, 보다 바람직하게는 0.01 ~ 3 중량%로 배합된다.Moreover, the compounding component which may be added other than this is not limited to this, Moreover, Although all said components can be mix | blended within the range which does not impair the objective and effect of this invention, Preferably it is 0.01-5 weight% with respect to a total weight, More preferably, it is mix | blended in 0.01 to 3 weight%.
본 발명의 화장료는 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다.The cosmetic of the present invention may take the form of a solution, an emulsion, a viscous mixture, or the like.
본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 조성물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체를 포함한다.Ingredients included in the cosmetic composition of the present invention may include components commonly used in cosmetic compositions in addition to the composition as an active ingredient, for example, conventional auxiliary agents such as stabilizers, solubilizers, vitamins, pigments and flavorings. And carriers.
본 발명의 피부질환 예방 및 개선용 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 유액, 크림, 화장수, 팩, 파운데이션, 로션, 미용액, 모발화장료 등을 들 수 있다.Cosmetic composition for preventing and improving skin diseases of the present invention can be prepared in any formulation commonly prepared in the art, for example, emulsion, cream, lotion, pack, foundation, lotion, essence, hair cosmetics, etc. Can be.
구체적으로, 본 발명의 화장료 조성물은 스킨로션, 스킨 소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스처 로션, 영양로션, 맛사지 크림, 영양크림, 모이스처 크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징 폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저의 제형을 포함한다.Specifically, the cosmetic composition of the present invention skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, Formulations of packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fibers, plant fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc. may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카 본, 프로판/부탄 또는 디메틸에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, and especially in the case of spray, additionally chlorofluorohydrocarbon, Propellant such as propane / butane or dimethylether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethyleneglycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, water, liquid diluents such as ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
이하, 본 발명은 실시예에 의거하여 더욱 상세하게 설명하겠는 바, 본 발명이 다음 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail based on Examples, but the present invention is not limited to the following Examples.
제조예 1: 대풍자 추출물의 제조Preparation Example 1 Preparation of Saengpung Extract
대풍자 240 g 잘게 세절 후 에탄올로 3시간씩 3회 추출하여 에탄올 추출액을 각각 얻고, 얻어진 추출물을 회전감압 농축 장치를 이용하여 에탄올을 제거한 후 에탄올 추출물을 얻었다.240 g of air sac was finely chopped and extracted three times with ethanol three times each to obtain an ethanol extract, and the obtained extract was removed using a rotary vacuum concentrator to obtain ethanol extract.
제조예 2: 5종 복합 생약 추출물의 제조Preparation Example 2 Preparation of Five Complex Herbal Extracts
대풍자 240 g, 호마자 120 g, 백선피 40 g, 목별자 40 g 및 백질려 32 g 잘게 세절, 혼합 후 에탄올로 3시간씩 3회 추출하여 에탄올 추출액을 각각 얻고, 얻어진 추출물을 회전감압 농축 장치를 이용하여 에탄올을 제거한 후 각각의 생약에 대한 에탄올 추출물을 얻었다.Saeng 240g, Hog 120g, white ginseng skin 40g, woodpecker 40g and white ginseng 32g finely chopped, mixed and extracted three times with ethanol three times each to obtain an ethanol extract, the obtained extract is a rotary decompression concentrator After ethanol was removed using the ethanol extract for each herbal medicine.
제조예 3: 6종 복합 생약 추출물의 제조Preparation Example 3 Preparation of Six Complex Herbal Extracts
상기 제조예 2에서 생약 혼합 시 고삼 40 g을 넣은 후 상기 제조예 2의 제조방법과 동일하게 수행하여 6종의 복합 생약 추출물을 수득하였다.40 g of wild ginseng was mixed in Preparation Example 2, and the same procedure as in Preparation Example 2 was performed to obtain six complex herbal extracts.
제조예 4: 19종의 복합 생약 추출물의 제조Preparation Example 4 Preparation of 19 Complex Herbal Extracts
상기 제조예 3에서 생약 혼합 시 창이자 40 g, 우방자 32 g, 만형자 32 g, 감국 32 g, 백하수오 40 g, 형개 40 g, 위령선 32 g, 박하 32 g, 용뇌 32 g, 석우황 20 g, 석창포 32 g, 전충 12 g 및 감초 32 g을 넣은 후 상기 제조예 2의 제조방 법과 동일하게 수행하여 19종의 복합 생약 추출물을 수득하였다.Changxiza 40 g, wooja 32 g, Manza 32 g, Gamuk 32 g, Baekshao 40 g, hyunggae 40 g, Maeulseon 32 g, Mint 32 g, Cerebrum 32 g, Sulfur sulfur 20 g , 32 g of Seokchangpo, 12 g of worms and 32 g of licorice were added, and the same procedure as in Preparation Example 2 was carried out to obtain 19 complex herbal extracts.
참고예 1: 약물 및 시약Reference Example 1: Drugs and Reagents
덱사메타손(Dexamethasone), 수산화알루미늄(Aluminum hydroxide), 난자 알부민(Ovum albumin), 클로로디니트로벤젠(1-chloro 2,4-dinitrobenzene; DNCB)은 Sigma-Aldrich Chemical Co.에서 구입하여 사용하였으며, 그 외 시약은 시중에서 구입할 수 있는 최상급을 사용하였다. 모든 한약재는 경동시장(Seoul, Korea)에서 구입하여 사용하였다. Dexamethasone, aluminum hydroxide, ovum albumin, and chlorodinitrobenzene (DNCB) were purchased from Sigma-Aldrich Chemical Co. and others. Reagents were of the highest quality available commercially. All herbal medicines were purchased from Gyeongdong market (Seoul, Korea).
참고예 2: 실험동물 준비Reference Example 2: Preparation of Laboratory Animals
4주령의 BALB/C 마우스(20 - 25 g)와 NC/Ng 마우스(20 - 25 g)를 (주) 중앙실험동물(Seoul, Korea)에서 공급받아 삼육대학교 의명신경과학연구소의 clean cage에 약 7일간 적응시켜 사용하였으며, 물과 사료는 자유롭게 섭취하도록 하였고, 온도(23 ± 2 ℃), 습도(55 ± 10 %) 및 명암주기(12 시간)는 자동으로 조절되도록 하였다.Four-week-old BALB / C mice (20-25 g) and NC / Ng mice (20-25 g) were supplied from a central laboratory animal (Seoul, Korea). It was used for 7 days, and water and feed were freely ingested, and the temperature (23 ± 2 ℃), humidity (55 ± 10%) and contrast cycle (12 hours) were automatically adjusted.
참고예 3: 통계 처리Reference Example 3: Statistics Processing
모든 실험 결과는 ANOVA(one way analysis of variance)를 이용하여 통계 처리하였고, Post-hoc test로 Newman-Keuls Test를 사용하여 p < 0.05 수준 이하에서 유의성 검정을 실시하였다. All experimental results were statistically analyzed using ANOVA (one way analysis of variance), and significance test was performed at p <0.05 level using Newman-Keuls Test as post-hoc test.
시험예 1: 아토피성 피부질환에 대한 대풍자 추출물의 치료 효능Experimental Example 1: Therapeutic Efficacy of Daengsugung Extract for Atopic Dermatitis
생후 4주령의 BALB/C 마우스를 1주일간 안정화를 시킨 후, 아토피비 유발군, 대조군(TWEEN 80 10%), 시험물질 투여군(제조예 1의 대풍자 추출물 50 mg/kg, 150 mg/kg, 400 mg/kg)과 양성대조군(Dexamethasone 5 mg/kg)으로 분류하여 시험을 실시하였다. After 4 weeks of age, the BALB / C mice were stabilized for 1 week, and then the atopy-induced group, the control group (TWEEN 80 10%), and the test substance-administered group (50 mg / kg, 150 mg / kg, 400 mg of Daegong extract of Preparation Example 1). mg / kg) and positive control group (
1) BALB/C 마우스에서 아토피성 피부염의 유발1) Induction of Atopic Dermatitis in BALB / C Mice
안정화 기간이 지난 후 마우스의 등을 귀 하단부에서부터 꼬리 상단부까지 전체를 제모한 후에 4% (w/w) 수산화알루미늄(Sigma) 용액 0.05 ml와 난자 알부민(OVA) 0.05 mg을 복강 주사한 후 3일째 되는 날 100 ㎕의 인산완충용액(PBS 용액)을 등에 도포하고 증발을 막기 위하여 Tegadum(2 x 2 cm)을 부착하였다. 나머지 군들은 100 ㎕의 PBS 용액과 0.1 mg OVA를 같은 방법으로 도포하고 부착하였다. 3일이 지난 후 부착한 패치를 떼어내고 2주일간의 잠복기를 두었다. 2주일 후 두 번째 피부자극을 위해 대조군은 50 ㎕의 PBS 용액을 복강 주사하였으며 다른 군들은 50 ㎕의 PBS 용액과 50 ㎍ OVA을 복강 주사하였다. 3일 후 첫 번째 패치를 부착하였던 것과 동일한 방법으로 등 피부에 두 번째 패치를 부착하였다. 3일 후 부착된 패치를 떼어내었다[Norikazu, 2003]. After the stabilization period, the mouse's back was removed from the bottom of the ear to the top of the tail, followed by intraperitoneal injection of 0.05 ml of 4% (w / w) aluminum hydroxide (Sigma) solution and 0.05 mg of egg albumin (OVA). 100 μl of phosphate buffer solution (PBS solution) was applied to the back and Tegadum (2 × 2 cm) was attached to prevent evaporation. The remaining groups were applied and attached with 100 μl of PBS solution and 0.1 mg OVA in the same manner. Three days later, the patch was removed and the incubation period was two weeks. Two weeks later, the control group was intraperitoneally injected with 50 μl of PBS solution for the second skin irritation, and the other groups were intraperitoneally injected with 50 μl of PBS solution and 50 μg OVA. Three days later, a second patch was attached to the back skin in the same way as the first patch. After 3 days, the attached patch was detached [Norikazu, 2003].
2) 시험약물의 투여2) Administration of test drug
대조군의 동물에는 TWEEN 80 10%용액을, 시험군의 동물에는 대풍자 추출물을 50 mg/kg, 150 mg/kg, 400 mg/kg의 용량으로, 양성대조군의 동물에는 덱사메타손(Dexamethasone)을 5 mg/kg의 용량으로 1일 1회, 오전 10:00 ~ 11:00시 사이에 2주일간 경구 투여하였다. 대풍자 추출물은 TWEEN 80 10% 용액에 현탁시켜 투여하였다. TWEEN 80 10% solution for the control animals, 50 mg / kg, 150 mg / kg, 400 mg / kg of the macrosatellite extract in the test animals, and 5 mg / of dexamethasone in the positive control animals. The dose of kg was orally administered once a day for 2 weeks between 10:00 AM and 11:00 AM. Daegongsae extract was administered suspended in a 10% solution of TWEEN 80.
3) 긁힘(Scratching behavior) 시험3) Scratching behavior test
시험물질을 투여 후 1, 3, 7, 14일이 되는 시점에 실시하였다. 시험물질 투여 한 시간 전과 시험물질 투여 후 30분부터 한 시간 동안 긁기 횟수(scratching counts)를 측정하였다[Norikazu, 2003]. 아토피성 피부염의 대표적인 증상인 염증 부위를 긁는 행동의 수를 기준으로 관찰하였다. Test substance was administered at 1, 3, 7, 14 days after administration. Scratching counts were measured one hour before the test substance administration and 30 minutes after the test substance administration (Norikazu, 2003). Observations were made based on the number of behaviors that scrape the inflammatory site, a typical symptom of atopic dermatitis.
도 1에서 보는 바와 같이 약물처치 3일째부터 14일째까지 대풍자 추출물(A) 투여군은 전용량군에서 대조군에 비해 긁는 횟수가 현저하게 감소하였으며, 그 감소 효능은 덱사메타손의 효능과 유사하였다. 이상의 결과는 대풍자 추출물을 3일 이상 투여하면 아토피성 피부염의 증상을 완화시킬 수 있음을 시사한다.As shown in Figure 1 from the 3rd to 14th day treatment with the saengpungsaeng extract (A) group significantly reduced the number of scratches in the full dose group compared to the control group, the reduction effect was similar to the efficacy of dexamethasone. The above results suggest that administration of the saengpung extract for more than 3 days can alleviate the symptoms of atopic dermatitis.
4) 관능 평가 시험 4) sensory evaluation test
시험물질을 투여 후 1, 3, 7, 14일이 되는 시점에 실시하였다. 본 평가 방법은 아토피성 피부염에서 일반적으로 사용되는 임상적 육안 평가법으로서 아토피성 피부염의 심각성 정도를 다음의 5가지 항목을 각각 평가한 점수의 총 합으로 나타낸다. 평가항목은 홍반(erythema), 가려움과 건조피부(Pruritus & Dry Skin), 부종과 혈종(Edema & escoriation), 짖무름(Erosion), 그리고 태선화 (Lichenification)로 나누어진다. 각각의 항목을 없음(0), 약함(1), 보통 (2), 심함(3)으로 채점한 후 합산함으로써 최소 0점에서 최고 15점 사이의 점수를 부여한다[Leung, et al., 1990; Suzuki, et al., 2002]. Test substance was administered at 1, 3, 7, 14 days after administration. This evaluation method is a clinical visual evaluation method commonly used in atopic dermatitis. The severity of atopic dermatitis is expressed as the sum of scores for each of the following five items. The endpoints were divided into erythema, itching and dry skin, edema and escoriation, erosion, and lichenification. Each item is scored as None (0), Weak (1), Moderate (2), and Severe (3) and summed to give a score between at least 0 and up to 15 points [Leung, et al., 1990 ; Suzuki, et al., 2002].
아토피성 피부염의 증상들을 종합하여 관찰한 관능평가 결과, 도 2에서 보는 바와 같이 약물 처치 7일째의 경우 대풍자 추출물 150 mg/kg과 400 mg/kg 투여군의 아토피성 피부염 점수가 대조군에 비해 유의성 있게 낮아졌고, 14일 째의 경우 전용량군에서 대조군에 비해 아토피성 피부염 점수가 유의성있게 감소하였다. 이상의 결과 역시 대풍자 추출물을 7일 이상 투여하면 아토피성 피부염의 증상을 완화시킬 있음을 시사한다.As a result of sensory evaluation, which is a combination of symptoms of atopic dermatitis, the atopic dermatitis scores of 150 mg / kg and 400 mg / kg of Saengpung extract were significantly lower than those of the control group, as shown in FIG. 2. At 14 days, atopic dermatitis scores were significantly decreased in the full dose group compared to the control group. The above results also suggest that administration of the saengpung extract for more than 7 days may alleviate the symptoms of atopic dermatitis.
5) 혈장 산호성 백혈구(eosinophil)와 IgE 함량의 측정5) Determination of plasma coral leukocytes (eosinophil) and IgE content
시험물질 투여 2 주가 되는 시점에 마우스를 마취시킨 후 심장 혈액을 채취하여 혈액분석기(네오딘벳랩, 서울)로 산호성 백혈구 수를 측정하고, 원심분리(3,500 rpm, 7분)한 후 혈청을 분리하여 -80 ℃에 보관했다가 ELISA kit(Shibayagi. co., Ltd. Japan)를 사용하여 산호성 백혈구와 Ig E의 함량을 측정하였다[Suzuki, et al, 2002; Kang. et al. 2006]. 아토피성 피부염의 발현시 나타나는 대표적인 혈액학적 변화인 산호성 백혈구와 IgE의 증가를 지표로 관찰하였다. 도 3에서 보는 바와 같이, 전 용량군에서 산호성 백혈구 수가 대조군에 비해 유의성 있게 감소하였고, 혈장 IgE의 함량은 대풍자 추출물 150 mg/kg과 400 mg/kg 투여군에서 대조군에 비해 유의성있게 감소하였다. 이상의 결과 역시 대풍자 추출물은 아토피성 피부염의 증상을 완화시킬 수 있으며, 그 증상의 완화는 알러지반응 억제작용과 관련이 있음을 시사한다. At 2 weeks after the administration of the test substance, the mouse was anaesthetized, cardiac blood was collected, and the blood leukocyte count was measured by a blood analyzer (Neodine Bevel Lab, Seoul), centrifuged (3,500 rpm, 7 minutes), and serum was separated. After storage at -80 ° C, the contents of coral leukocytes and Ig E were measured using an ELISA kit (Shibayagi. Co., Ltd. Japan) [Suzuki, et al, 2002; Kang. et al. 2006]. An increase in coral leukocytes and IgE, a representative hematological change in the expression of atopic dermatitis, was observed. As shown in FIG. 3, the number of coral leukocytes in the full dose group was significantly decreased compared to the control group, and the plasma IgE content was significantly decreased in the control group in the 150 mg / kg and 400 mg / kg administration groups. The results also suggest that the saengpung extract can alleviate the symptoms of atopic dermatitis, and the alleviation of the symptoms is related to allergic reactions.
시험예 2: 아토피성 피부질환에 대한 생약 복합 추출물(5종)의 치료 효능Experimental Example 2: Therapeutic Efficacy of Herbal Combination Extract (5 Types) against Atopic Dermatitis
생후 4주령의 BALB/C 마우스를 1주일간 안정화를 시킨 후 아토피 비유발군, 대조군(TWEEN 80 10%), 시험물질 투여군(제조예 2의 5종 생약 복합 추출물 40 mg/kg, 200 mg/kg, 500 mg/kg)과 양성대조군(Dexamethasone 5 mg/kg)으로 분류하여 시험을 실시하였다.BALB / C mice at 4 weeks of age were stabilized for 1 week, after which atopic dermatitis-induced group, control group (TWEEN 80 10%), test substance-administered group (5 herbal compound combination extract of Preparation Example 2 40 mg / kg, 200 mg / kg, 500 mg / kg) and positive control (
1) BALB/C 마우스에서 아토피성 피부염의 유발1) Induction of Atopic Dermatitis in BALB / C Mice
안정화 기간이 지난 후 마우스의 등을 귀 하단부에서부터 꼬리 상단부까지 전체를 제모한 후에 4%(w/w) 수산화알루미늄(Sigma) 용액 0.05 ml와 난자 알부민(OVA) 0.05 mg을 복강 주사한 후 3일째 되는 날 100 ㎕의 인산완충용액(PBS 용액)을 등에 도포하고 증발을 막기 위하여 Tegadum(2 x 2 cm)을 부착하였다. 나머지 군들은 100 ㎕의 PBS 용액과 0.1 mg OVA를 같은 방법으로 도포하고 부착하였다. 3일이 지난 후 부착한 패치를 떼어내고 2주일간의 잠복기를 두었다. 2주일 후 두 번째 피부자극을 위해 대조군은 50 ㎕의 PBS 용액을 복강 주사하였으며 다른 군들은 50 ㎕의 PBS 용액과 50 ㎍ OVA을 복강 주사하였다. 3일 후 첫 번째 패치를 부착하였던 것과 동일한 방법으로 등 피부에 두 번째 패치를 부착하였다. 3일 후 부착된 패치를 떼어내었다. After the stabilization period, the mouse's back was removed from the bottom of the ear to the top of the tail, followed by intraperitoneal injection of 0.05 ml of 4% (w / w) aluminum hydroxide (Sigma) solution and 0.05 mg of egg albumin (OVA). 100 μl of phosphate buffer solution (PBS solution) was applied to the back and Tegadum (2 × 2 cm) was attached to prevent evaporation. The remaining groups were applied and attached with 100 μl of PBS solution and 0.1 mg OVA in the same manner. Three days later, the patch was removed and the incubation period was two weeks. Two weeks later, the control group was intraperitoneally injected with 50 μl of PBS solution for the second skin irritation, and the other groups were intraperitoneally injected with 50 μl of PBS solution and 50 μg OVA. Three days later, a second patch was attached to the back skin in the same way as the first patch. After 3 days the attached patch was removed.
2) 시험약물의 투여2) Administration of test drug
대조군의 동물에는 TWEEN 80 10% 용액을, 시험군의 동물에는 5종 복합 생약 추출물을 40 mg/kg, 200 mg/kg, 500 mg/kg의 용량으로, 양성대조군의 동물에는 덱사메타손(Dexamethasone)을 5 mg/kg의 용량으로 1일 1회, 오전 10:00 ~ 11:00시 사이에 2주일간 경구 투여하였다.TWEEN 80 10% solution for control animals, 5 compound herbal extracts of 40 mg / kg, 200 mg / kg, 500 mg / kg for test animals, and dexamethasone for positive control animals. The dose of 5 mg / kg was orally administered once a day for 2 weeks between 10:00 AM and 11:00 AM.
3) 긁힘(Scratching Behavior) 시험3) Scratching Behavior Test
시험물질을 투여 후 1, 3, 7, 14일이 되는 시점에 실시하였다. 시험물질 투여 한 시간 전과 시험물질 투여 후 30분부터 한 시간 동안 긁힘 횟수 (scratching counts)를 측정하였다.Test substance was administered at 1, 3, 7, 14 days after administration. Scratching counts were measured one hour before the test substance administration and 30 minutes after the test substance administration.
아토피성 피부염의 대표적인 증상인 염증 부위를 긁는 행동의 수를 기준으로 관찰하였다. 약물처치 3일째 14일까지 5종 생약 복합 추출물 투여군은 전용량군에서 대조군에 비해 긁힘 횟수가 현저하게 감소하였으며 그 감소 효능은 덱사메타손의 효능과 유사하거나 더 강하였다[도 4]. 약물처치 전보다 약물처치 후에 감소하는 정도가 더 강한 경향을 나타내었다. 이상의 결과는 5종 생약 복합 추출물을 3일 이상 투여하면 아토피성 피부염의 증상을 완화시킬 수 있었다.Observations were made based on the number of behaviors that scrape the inflammatory site, a typical symptom of atopic dermatitis. By the 14th day of the treatment, the four herbal compound extracts were significantly reduced the number of scratches in the full dose group compared to the control group, and the reduction effect was similar to or stronger than that of dexamethasone [FIG. 4]. The tendency to decrease after treatment was stronger than before treatment. The above results could alleviate the symptoms of atopic dermatitis by administering five herbal extracts for more than three days.
4) 관능 평가 시험 4) sensory evaluation test
시험물질을 투여 후 1, 3, 7, 14일이 되는 시점에 실시하였다. 본 평가 방법은 아토피성 피부염에서 일반적으로 사용되는 임상적 육안 평가법으로서 아토피성 피부염의 심각성 정도를 다음의 5가지 항목을 각각 평가한 점수의 총합으로 나타낸다. 평가항목은 홍반(erythema), 가려움과 건조피부(Pruritus & Dry Skin), 부종과 혈종(Edema & escoriation), 짖무름(Erosion), 그리고 태선화 (Lichenification)로 나누어진다. 각각의 항목을 없음(0), 약함(1), 보통 (2), 심함(3)으로 채점한 후 합산함으로써 최소 0점에서 최고 15점 사이의 점수를 부여한다. Test substance was administered at 1, 3, 7, 14 days after administration. This evaluation method is a clinical visual evaluation method commonly used in atopic dermatitis. The severity of atopic dermatitis is expressed as the sum of scores for each of the following five items. The endpoints were divided into erythema, itching and dry skin, edema and escoriation, erosion, and lichenification. Each item is scored as None (0), Weak (1), Moderate (2), and Severe (3) and summed to give a score between 0 and 15 points.
아토피성 피부염의 증상들을 종합하여 관찰한 관능평가 결과 약물처치 3일째와 7일째의 경우 5종 생약 복합 추출물 200 mg/kg과 500 mg/kg 투여군의 아토피성 피부염 점수가 대조군에 비해 유의성 있게 낮아졌고, 14일 째의 경우 전용량군에서 대조군에 비해 아토피성 피부염 점수가 유의성 있게 감소하였다[도 5]. 그 감소 효능은 덱사메타손의 효능과 유사하거나 더 강하였다. 이상의 결과 역시 5종 생약 복합 추출물을 3일 이상 투여하면 아토피성 피부염의 증상을 완화시킬 수 있음을 시사한다.According to the results of sensory evaluation by combining the symptoms of atopic dermatitis, the atopic dermatitis scores of 200 mg / kg and 500 mg / kg combinations of five herbal extracts were significantly lower than those of the control group on the 3rd and 7th day of treatment. On the 14th day, the atopic dermatitis score was significantly decreased in the full dose group compared to the control group [FIG. 5]. The decreasing efficacy was similar or stronger than that of dexamethasone. The above results also suggest that administration of five herbal extracts for more than 3 days may alleviate the symptoms of atopic dermatitis.
5) 혈장 IgE와 IL-4 수치의 측정5) Measurement of Plasma IgE and IL-4 Levels
시험물질 투여 2 주가 되는 시점에 마우스를 마취시킨 후 심장 혈액을 채취하여 원심분리(3,500 rpm, 7분)한 후 혈청을 분리하여 -80℃에 보관했다가 ELISA kit(Shibayagi. co., Ltd. Japan)를 사용하여 IgE와 IL-4의 함량을 측정하였다.Two weeks after the test substance was administered, mice were anesthetized, heart blood was collected, centrifuged (3,500 rpm, 7 minutes), serum was separated, stored at -80 ° C, and then ELISA kit (Shibayagi. Co., Ltd. Japan) was used to measure the content of IgE and IL-4.
아토피성 피부염의 발현시 나타나는 대표적인 혈액학적 변화인 IL4와 IgE를 지표로 관찰하였다. 혈장 IgE와 IL-4의 함량변화는 염증반응 및 면역반응의 정도를 예표하며, 특별히, IgE는 알러지 반응의 정도를 나타내는 지표가 된다. IL4의 경우 아토피성 피부염의 유발에 의해 혈중 농도가 증가하였으나 5종 복합 생약 추출물 200 mg/kg과 덱사메타손 5 mg/kg 투여에 의해 유의성 있게 회복되었다. IgE 역시 아토피성 피부염의 유발에 의해 혈중농도가 증가하였으나 5종 복합 생약 추출물 40, 200, 500 mg/kg 및 덱사메타손 5 mg/kg 투여에 의해 유의성 있게 회복되었다[도 6]. 혈중 IgE와 IL-4의 함량 변화에 대한 5종 복합 생약 추출물의 효능 역시 덱사메타손의 효능과 유사하거나 더 강하였다. 이상의 결과 역시 5종 복합 생약 추출물은 아토피성 피부염의 증상을 완화시킬 수 있으며, 그 증상의 완화는 알러지 반응 억제 작용과 관련이 있음을 시사한다.IL4 and IgE, which are representative hematological changes in the expression of atopic dermatitis, were observed as indicators. Changes in plasma levels of IgE and IL-4 exemplify the extent of inflammatory and immune responses. In particular, IgE is an indicator of the extent of allergic reactions. In the case of IL4, blood concentration was increased by the induction of atopic dermatitis, but was significantly recovered by the administration of 200 mg / kg of five complex herbal extracts and 5 mg / kg of dexamethasone. IgE also increased blood levels due to the induction of atopic dermatitis, but was significantly recovered by administration of five complex
시험예 3: 아토피성 피부질환에 대한 생약 복합 추출물(6종)의 치료 효능Experimental Example 3: Therapeutic Efficacy of Herbal Combination Extract (6 Species) against Atopic Dermatitis
생후 4주령의 NC/Nga 마우스를 1주일간 안정화를 시킨 후 아토피 비유발군, 대조군(TWEEN 80 10%), 시험물질 투여군(제조예 3의 6종 생약 복합 추출물 40 mg/kg, 200 mg/kg, 500 mg/kg)과 양성대조군(Dexamethasone 5 mg/kg)으로 분류하여 시험을 실시하였다.NC / Nga mice at 4 weeks of age were stabilized for 1 week, after which atopic dermatitis-induced group, control group (TWEEN 80 10%), test substance-administered group (6 herbal compound complex extracts of Preparation Example 3 40 mg / kg, 200 mg / kg, 500 mg / kg) and positive control (
1) 아토피 유발 시험1) Atopic Induction Test
안정화 기간이 지난 후 마우스의 등을 귀 하단부에서부터 꼬리 상단부까지 전체를 제모하고 24시간 방치한 후 면역(Immunization)을 유도하기 위해 1% DNCB 용액(아세톤 : 올리브오일=3:1) 200 ㎕를 제모 부위에 도포하였다. 도포 4일 후, 1주일에 3회씩 5주간 0.2% DNCB 용액 150㎕를 재 도포하여 아토피성 피부염을 유발하였다.After the stabilization period, the mouse's back is epilated from the bottom of the ear to the top of the tail and left for 24 hours, followed by 200 μl of 1% DNCB solution (acetone: olive oil = 3: 1) to induce immunization. It was applied to the site. After 4 days of application, 150 μl of 0.2% DNCB solution was re-applied three times a week for 5 weeks to induce atopic dermatitis.
2) 시험약물의 투여2) Administration of test drug
DNCB 처리를 종료한 후, 대조군의 동물에는 TWEEN 80 10% 용액을, 시험군의 동물에는 6종 복합 생약 추출물을 40 mg/kg, 200 mg/kg, 500 mg/kg의 용량으로, 양성대조군의 동물에는 덱사메타손(Dexamethasone)을 5 mg/kg의 용량으로 1일 1회, 오전 10:00~11:00시 사이에 1주일간 경구 투여하였다.After the DNCB treatment, the control animals were treated with a 10% solution of
3) 긁힘(Scratching Behavior) 시험3) Scratching Behavior Test
시험물질을 투여 후 1, 3, 7일이 되는 시점에 실시하였다. 시험물질 투여 한 시간 전과 시험물질 투여 후 30분부터 한 시간 동안 긁힘 횟수(scratching counts)를 측정하였다.Test substance was administered at 1, 3, 7 days after administration. Scratching counts were measured one hour before the test substance administration and 30 minutes after the test substance administration.
아토피성 피부염의 대표적인 증상인 염증 부위를 긁는 행동의 수를 기준으로 관찰하였다. 약물처치 첫날 6종 복합 생약 추출물 투여 후 전용량군에서 대조군에 비해 긁힘 횟수가 유의성 있게 감소하였고, 200 mg/kg과 500 mg/kg 투여군에서는 투여 전에 비해서도 긁힘 횟수가 유의성 있게 감소하였으며, 그 감소 효능은 덱사메타손의 효능과 유사하거나 더 강하였다[도 7]. 이상의 결과는 6종 복합 생약 추출물을 투여하면 아토피성 피부염의 증상을 완화시킬 수 있음을 시사한 다. Observations were made based on the number of behaviors that scrape the inflammatory site, a typical symptom of atopic dermatitis. The number of scratches was significantly decreased in the full dose group compared to the control group after the six combination herbal extracts were administered on the first day of the treatment, and the number of scratches was significantly reduced in the 200 mg / kg and 500 mg / kg groups compared with the control group. Was similar or stronger than the efficacy of dexamethasone [FIG. 7]. The above results suggest that administration of six herbal extracts can alleviate the symptoms of atopic dermatitis.
4) 관능 평가 시험 4) sensory evaluation test
시험물질을 투여 후 1, 3, 7일이 되는 시점에 실시하였다. 본 평가방법은 아토피성 피부염에서 일반적으로 사용되는 임상적 육안 평가법으로서 아토피성피부염의 심각성 정도를 다음의 5가지 항목을 각각 평가한 점수의 총합으로 나타낸다. 평가항목은 홍반(erythema), 가려움과 건조피부(Pruritus & Dry Skin), 부종과 혈종(Edema & escoriation), 짖무름(Erosion), 그리고 태선화 (Lichenification)로 나누어진다. 각각의 항목을 없음(0), 약함(1), 보통 (2), 심함(3)으로 채점한 후 합산함으로써 최소 0점에서 최고 15점 사이의 점수를 부여한다. Test substance was administered at 1, 3, 7 days after administration. This evaluation method is a clinical visual evaluation method commonly used in atopic dermatitis. The severity of atopic dermatitis is expressed as the sum of scores for each of the following five items. The endpoints were divided into erythema, itching and dry skin, edema and escoriation, erosion, and lichenification. Each item is scored as None (0), Weak (1), Moderate (2), and Severe (3) and summed to give a score between 0 and 15 points.
아토피성 피부염의 증상들을 종합하여 관찰한 관능평가 결과, 약물처치 3일째와 7일째의 경우 6종 복합 생약 추출물 200 mg/kg과 500 mg/kg 투여군의 아토피성 피부염 점수가 대조군에 비해 유의성 있게 감소하였다[도 8]. 그 감소 효능은 덱사메타손의 효능과 유사하거나 더 강하였다. 이상의 결과 역시 6종 복합 생약 추출물을 투여하면 아토피성 피부염의 증상을 완화시킬 수 있음을 시사한다.According to the results of sensory evaluation by combining the symptoms of atopic dermatitis, the atopic dermatitis scores of 200 mg / kg and 500 mg / kg of the six combination herbal extracts were significantly decreased in the 3rd and 7th day of treatment. [FIG. 8]. The decreasing efficacy was similar or stronger than that of dexamethasone. The above results also suggest that administration of the six herbal extracts can alleviate the symptoms of atopic dermatitis.
5) 혈장 IgE와 IL-4 수치의 측정5) Measurement of Plasma IgE and IL-4 Levels
시험물질 투여 1주가 되는 시점에 마우스를 마취시킨 후 심장 혈액을 채취하여 원심분리(3,500 rpm, 7분)한 후 혈청을 분리하여 -80 ℃에 보관했다가 ELISA kit(Shibayagi. co., Ltd. Japan)를 사용하여 IgE와 IL-4의 함량을 측정하였다. After 1 week of administration of the test substance, mice were anesthetized, heart blood was collected, centrifuged (3,500 rpm, 7 minutes), serum was separated, stored at -80 ° C, and the ELISA kit (Shibayagi. Co., Ltd. Japan) was used to measure the content of IgE and IL-4.
아토피성 피부염의 발현시 나타나는 대표적인 혈액학적 변화인 IL4와 IgE를 지표로 관찰하였다. 혈장 IgE와 IL-4의 함량 변화는 염증반응 및 면역반응의 정도를 예표하며, 특별히, IgE는 알러지 반응의 정도를 나타내는 지표가 된다. IL4의 경우 아토피성 피부염의 유발에 의해 혈중농도가 증가하였으나 6종 복합 생약 추출물 200 mg/kg과 덱사메타손 5 mg/kg 투여에 의해 유의성 있게 회복되었다. IgE 역시 아토피성피부염의 유발에 의해 혈중농도가 증가하였으나 6종 복합 생약 추출물 500 mg/kg 투여에 의해 유의성 있게 회복되었다[도 9]. 혈중 IgE와 IL-4의 함량 변화에 대한 6종 복합 생약 추출물의 효능 역시 덱사메타손의 효능과 유사하거나 더 강하였다. 이상의 결과 역시 6종 복합 생약 추출물은 아토피성 피부염의 증상을 완화시킬 수 있으며, 그 증상의 완화는 알러지 반응 억제작용과 관련이 있음을 시사한다.IL4 and IgE, which are representative hematological changes in the expression of atopic dermatitis, were observed as indicators. Changes in plasma levels of IgE and IL-4 foreshadow the extent of inflammatory and immune responses, and in particular, IgE is an indicator of the extent of allergic reactions. In the case of IL4, the blood concentration was increased by the induction of atopic dermatitis, but it was significantly recovered by the administration of 200 mg / kg of 6 herbal extracts and 5 mg / kg of dexamethasone. IgE also increased blood levels due to the induction of atopic dermatitis, but recovered significantly by administration of 500 mg / kg of the six complex herbal extracts [FIG. 9]. The efficacy of the six herbal extracts on the changes of IgE and IL-4 levels in the blood was similar or stronger than that of dexamethasone. The above results also suggest that the six herbal extracts can alleviate the symptoms of atopic dermatitis, and the alleviation of the symptoms is related to allergic reaction inhibitory action.
시험예 4: 아토피성 피부질환에 대한 생약 복합 추출물(19종)의 치료 효능Test Example 4: Therapeutic Efficacy of Herbal Combination Extract (19 Types) against Atopic Dermatitis
생후 4주령의 BALB/C 마우스를 1주일간 안정화를 시킨 후 아토피 비유발군, 대조군(TWEEN 80 10%), 시험물질 투여군(제조예 4의 19종 생약 복합 추출물 100 mg/kg, 500 mg/kg)과 양성대조군(Dexamethasone 5 mg/kg)으로 분류하여 시험을 실시하였다.BALB / C mice at 4 weeks of age were stabilized for 1 week, after which atopic non-induced group, control group (TWEEN 80 10%), test substance-administered group (complex extract of 19 kinds of herbal medicines of Preparation Example 4 100 mg / kg, 500 mg / kg) The test was performed by classifying into a positive control group (
1) BALB/C 마우스에서 아토피성 피부염의 유발1) Induction of Atopic Dermatitis in BALB / C Mice
안정화 기간이 지난 후 마우스의 등을 귀 하단부에서부터 꼬리 상단부까지 전체를 제모한 후에 4%(w/w) 수산화알루미늄(Sigma) 용액 0.05 ml와 난자 알부민(OVA) 0.05 mg을 복강 주사한 후 3일째 되는 날 100 ㎕의 인산완충용액(PBS 용액)을 등에 도포하고 증발을 막기 위하여 Tegadum(2 x 2 cm)을 부착하였다. 나머지 군들은 100 ㎕의 PBS 용액과 0.1 mg OVA를 같은 방법으로 도포하고 부착하였다. 3일이 지난 후 부착한 패치를 떼어내고 2주일간의 잠복기를 두었다. 2주일 후 두 번째 피부자극을 위해 대조군은 50 ㎕의 PBS 용액을 복강 주사하였으며 다른 군들은 50 ㎕의 PBS 용액과 50 ㎍ OVA을 복강 주사하였다. 3일 후 첫 번째 패치를 부착하였던 것과 동일한 방법으로 등 피부에 두 번째 패치를 부착하였다. 3일 후 부착된 패치를 떼어내었다. After the stabilization period, the mouse's back was removed from the bottom of the ear to the top of the tail, followed by intraperitoneal injection of 0.05 ml of 4% (w / w) aluminum hydroxide (Sigma) solution and 0.05 mg of egg albumin (OVA). 100 μl of phosphate buffer solution (PBS solution) was applied to the back and Tegadum (2 × 2 cm) was attached to prevent evaporation. The remaining groups were applied and attached with 100 μl of PBS solution and 0.1 mg OVA in the same manner. Three days later, the patch was removed and the incubation period was two weeks. Two weeks later, the control group was intraperitoneally injected with 50 μl of PBS solution for the second skin irritation, and the other groups were intraperitoneally injected with 50 μl of PBS solution and 50 μg OVA. Three days later, a second patch was attached to the back skin in the same way as the first patch. After 3 days the attached patch was removed.
2) 시험약물의 투여2) Administration of test drug
대조군의 동물에는 TWEEN 80 10% 용액을, 시험군의 동물에는 19종 복합 생약 추출물을 100 mg/kg, 400 mg/kg의 용량으로, 양성대조군의 동물에는 덱사메타손(Dexamethasone)을 5 mg/kg의 용량으로 1일 1회, 오전 10:00~11:00시 사이에 2주일간 경구 투여하였다.TWEEN 80 10% solution was used in the control animals, and 19 mg of the herbal extracts in the test group were dosed at 100 mg / kg and 400 mg / kg, and dexamethasone was 5 mg / kg in the positive control animals. The dose was administered orally once a day for two weeks between 10:00 AM and 11:00 AM.
3) 긁힘(Scratching Behavior) 시험3) Scratching Behavior Test
시험물질을 투여 후 1, 3, 7, 14일이 되는 시점에 실시하였다. 시험물질 투여 한 시간 전과 시험물질 투여 후 30분부터 한 시간 동안 긁힘 횟수(scratching counts)를 측정하였다.Test substance was administered at 1, 3, 7, 14 days after administration. Scratching counts were measured one hour before the test substance administration and 30 minutes after the test substance administration.
약물처치 3일째 14일까지 19종 생약 복합 추출물 투여군은 전 용량군에서 대조군에 비해 긁힘 횟수가 현저하게 감소하였으며 그 감소 효능은 덱사메타손의 효능과 유사하거나 더 강하였다[도 10]. 이상의 결과는 19종 생약 복합 추출물을 3일 이상 투여하면 아토피성 피부염의 증상을 완화시킬 수 있었다.By the 14th day of treatment, the group of 19 herbal compound extracts was significantly reduced in the number of scratches in the full dose group compared to the control group, and the reduction effect was similar to or stronger than that of dexamethasone [FIG. 10]. The above results could alleviate the symptoms of atopic dermatitis when administered over 19 days with 19 herbal extracts.
4) 관능 평가 시험 4) sensory evaluation test
시험물질을 투여 후 1, 3, 7, 14일이 되는 시점에 실시하였다. 본 평가방법은 아토피성 피부염에서 일반적으로 사용되는 임상적 육안 평가법으로서 아토피성 피부염의 심각성 정도를 다음의 5가지 항목을 각각 평가한 점수의 총합으로 나타낸다. 평가항목은 홍반(erythema), 가려움과 건조피부(Pruritus & Dry Skin), 부종과 혈종(Edema & escoriation), 짖무름(Erosion), 그리고 태선화(Lichenification)로 나누어진다. 각각의 항목을 없음(0), 약함(1), 보통 (2), 심함(3)으로 채점한 후 합산함으로써 최소 0점에서 최고 15점 사이의 점수를 부여한다. Test substance was administered at 1, 3, 7, 14 days after administration. This evaluation method is a clinical visual evaluation method commonly used in atopic dermatitis. The severity of atopic dermatitis is expressed as the sum of scores for each of the following five items. The assessment items are divided into erythema, itching and dry skin, edema and edema, edema and erosion, and lichenification. Each item is scored as None (0), Weak (1), Moderate (2), and Severe (3) and summed to give a score between 0 and 15 points.
아토피성 피부염의 증상들을 종합하여 관찰한 관능평가 결과, 약물처치 7일째, 14일째의 경우 19종 생약 복합 추출물 전용량군에서 대조군에 비해 아토피성 피부염 점수가 유의성 있게 감소하였다[도 11]. 그 감소 효능은 덱사메타손의 효능과 유사하거나 더 강하였다. 이상의 결과 역시 19종 생약 복합 추출물을 3일 이상 투여하면 아토피성 피부염의 증상을 완화시킬 수 있음을 시사한다.As a result of sensory evaluation by combining the symptoms of atopic dermatitis, atopic dermatitis scores were significantly reduced in the group of 19 herbal compound extracts only on the 7th and 14th day of drug treatment compared to the control group [FIG. 11]. The decreasing efficacy was similar or stronger than that of dexamethasone. The above results also suggest that administration of the 19 herbal extracts for more than 3 days may alleviate the symptoms of atopic dermatitis.
시험예 4: 랫트에 대한 경구투여 급성 독성실험Test Example 4: Oral Administration of Rats Acute Toxicity
6주령의 특정병원부재(SPF) SD계 랫트를 사용하여 급성독성실험을 다음과 같이 실시하였다. Acute toxicity test was performed using 6-week-old SPF SD rats as follows.
군당 2 마리씩의 동물에 대풍자 추출물 또는 생약 복합 추출물을 각각 용해시켜 1 g/kg 용량으로 단회 경구 투여하였다. 시험물질 투여 후 동물의 폐사 여부, 임상증상, 체중변화를 관찰하고 혈액학적 검사와 혈액생화학적 검사를 실시하였으며, 부검하여 육안으로 복강장기와 흉강장기의 이상 여부를 관찰하였다. Two animals per group were dissolved in the macrosatellite extract or the herbal extract, respectively, and administered once orally at a dose of 1 g / kg. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed. Necropsy was performed to observe abdominal and thoracic organ abnormalities.
그 결과, 시험물질을 투여한 모든 동물에서 특기할 만한 임상증상이나 폐사된 동물은 없었으며, 체중변화, 혈액검사, 혈액생화학 검사, 부검소견 등에서도 독성변화는 관찰되지 않았다. 따라서, 본 발명에 따른 대풍자 추출물 또는 생약 복합 추출물은 모든 랫트에서 2000 mg/kg까지 독성변화를 나타내지 않았다.As a result, no significant clinical symptoms or dead animals were noted in all animals treated with the test substance, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings. Therefore, saengsugung extract or herbal extract according to the present invention did not show a toxicity change to 2000 mg / kg in all rats.
제제예 1: 산제의 제조Formulation Example 1 Preparation of Powder
대풍자 추출물 또는 생약 복합 추출물 300 mgSaenggi extract or
유당 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above ingredients were mixed and filled in an airtight cloth to prepare a powder.
제제예 2: 정제의 제조Formulation Example 2: Preparation of Tablet
대풍자 추출물 또는 생약 복합 추출물 300 mgSaenggi extract or
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components was prepared by tableting according to the conventional manufacturing method of the tablet.
제제예 3: 캅셀제의 제조Formulation Example 3: Preparation of Capsule
대풍자 추출물 또는 생약 복합 추출물 300 mgSaenggi extract or
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium Stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.According to a conventional capsule preparation method, the above ingredients were mixed and filled into gelatin capsules to prepare capsules.
제제예 4: 주사제의 제조Formulation Example 4 Preparation of Injection
대풍자 추출물 또는 생약 복합 추출물 300 mgSaenggi extract or
만니톨 180 mgMannitol 180 mg
주사용 멸균 증류수 2974 mgSterile distilled water for injection 2974 mg
Na2HPO4 ·12H2O 26 mg Na 2 HPO 4 · 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당(2 ㎖) 상기의 성분 함량으로 제조하였다.According to the conventional method for preparing an injection, the amount of the above ingredient was prepared per ampoule (2 ml).
제제예 5: 액제의 제조Formulation Example 5 Preparation of Liquid
대풍자 추출물 또는 생약 복합 추출물 300 mgSaenggi extract or
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ㎖로 조절한 후 갈색 병에 충진하여 멸균시켜 액제를 제조하였다.According to the conventional method of preparing a liquid solution, each component is added to the purified water to dissolve, the lemon flavor is added appropriately, the above components are mixed, purified water is added, the whole is adjusted to 100 ml by the addition of purified water, and then filled into a brown bottle. The solution was prepared by sterilization.
제제예 6: 연고제의 제조 Formulation Example 6: Preparation of Ointment
대풍자 추출물 또는 생약 복합 추출물 80 중량부를 이용하여 다음과 같은 조성으로 연고제를 제조하였다. Using the 80 parts by weight of the extract of saengpung or herbal extracts ointment was prepared in the following composition.
[조성] [Furtherance]
유효성분 5 g, 세틸팔미테이트 20 g, 세탄올 40 g, 스테아릴알코올 40 g, 미 리스탄이소프로필 80 g, 모노스테아린산 소르비탄 20 g, 폴리솔베이트 60 g, 파라옥시안식향산 프로필 1 g, 파라옥시안식향산 메틸 1 g, 인산 및 정제수 적량 Active ingredient 5 g, cetyl palmitate 20 g, cetanol 40 g, stearyl alcohol 40 g, myristan isopropyl 80 g, monostearic acid sorbitan 20 g, polysorbate 60 g, paraoxybenzoic acid propyl 1 g, 1 g of methyl paraoxybenzoate, phosphoric acid and purified water
제제예 7: 건강보조식품의 제조Formulation Example 7 Preparation of Dietary Supplement
대풍자 추출물 또는 생약 복합 추출물 1000 ㎎Daegong Extract or Herbal Extract 1000 mg
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎0.13 mg of vitamin B 1
비타민 B2 0.15 ㎎0.15 mg of vitamin B 2
비타민 B6 0.5 ㎎0.5 mg of vitamin B 6
비타민 B12 0.2 ㎍Vitamin B 12 0.2 g
비타민 C 10 ㎎
비오틴 10 ㎍10 μg biotin
니코틴산아미드 1.7 ㎎Nicotinic Acid 1.7 mg
엽산 50 ㎍50 μg folic acid
판토텐산 칼슘 0.5 ㎎Calcium Pantothenate 0.5mg
무기질 혼합물 적량Mineral mixture
황산제1철 1.75 ㎎Ferrous Sulfate 1.75 mg
산화아연 0.82 ㎎Zinc Oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎Dibasic calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium Citrate 90 mg
탄산칼슘 100 ㎎
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
제제예 8: 건강 음료의 제조Formulation Example 8: Preparation of Healthy Drinks
대풍자 추출물 또는 생약 복합 추출물 1000 ㎎Daegong Extract or Herbal Extract 1000 mg
구연산 1000 ㎎Citric acid 1000 mg
올리고당 100 g100 g oligosaccharides
매실농축액 2 gPlum concentrate 2 g
타우린 1 g1 g of taurine
정제수를 가하여 전체 900 ㎖Add 900 ml of purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동 안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 ℓ 용기에 취득하여 밀봉, 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용하였다. 상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.After mixing the above components according to the conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed, sterilized and refrigerated Next was used to prepare a health beverage composition of the present invention. Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.
제제예 9: 목욕액의 제조Formulation Example 9 Preparation of Bath Liquid
DL-락트산나트륨 21 중량부, 피루브산 나트륨 8 중량부, 대풍자 추출물 또는 생약 복합 추출물 45 중량부와 정제수 26 중량부 및 적당량의 색소와 향료를 혼합하여 목욕액을 제조할 수 있다. 이 제품은 사용할 때에 목욕물 중에 100 ~ 10,000 배로 희석하여 피부질환 개선용 목욕제로 사용하기 적합하다. 이 경우에 있어서 목욕물 대신에 클렌징액, 수렴액 및 보습액을 사용할 수 있다.A bath solution may be prepared by mixing 21 parts by weight of DL-sodium lactate, 8 parts by weight of sodium pyruvate, 45 parts by weight of saucy extract or herbal extract, 26 parts by weight of purified water, and an appropriate amount of pigment and flavor. It is suitable for use as a bath for improving skin diseases by diluting 100 to 10,000 times in bath water when used. In this case, a cleansing liquid, astringent liquid and a moisturizing liquid can be used instead of the bath water.
제제예 10: 스킨로션의 제조Formulation Example 10 Preparation of Skin Lotion
정제수에 글리세린 3 중량부, 부틸렌글리콜 2 중량부, 프로필렌글리콜 2 중량부, 방부제를 투입하여 교반하여 용해시킨 후 폴리옥시에틸렌(60) 경화 피마자유 1 중량부를 60 ℃정도 가열하여 용해시킨 후 향료를 투입 교반하여 정제수 80.9 중량부에 투입하였다. 마지막으로 대풍자 추출물 또는 생약 복합 추출물 1 중량부, 에탄올 10 중량부, 트리에탄올 아민 0.1 중량부, 색소를 투입하여 충분히 교반하여 표제의 제품을 얻었다. 이 제품은 고품질의 피부 미용제 및 피부질환 개 선제로 사용된다.3 parts by weight of glycerin, 2 parts by weight of butylene glycol, 2 parts by weight of propylene glycol, and preservatives were added and dissolved in purified water, and then 1 part by weight of polyoxyethylene (60) cured castor oil was dissolved by heating to 60 ° C. Was added and stirred to add 80.9 parts by weight of purified water. Finally, 1 part by weight of the macrosporum extract or the herbal extract extract, 10 parts by weight of ethanol, 0.1 parts by weight of triethanol amine, and a pigment were added thereto, followed by sufficiently stirring to obtain the title product. This product is used as a high quality skin beauty and skin disease improvement agent.
제제예 11: 밀크로션(영양로션)의 제조Formulation Example 11 Preparation of Milk Lotion (Nutrition Lotion)
시토 스테롤 1.7 중량부, 폴리글리세릴 2-올레이트 1.5 중량부, 세라마이드 0.7 중량부, 세테아레스-4 1.2 중량부, 콜레스테롤 1.5 중량부를 일정한 온도에서 균질화하고, 대풍자 추출물 또는 생약 복합 추출물 1 중량부 및 디세틸포스페이트 0.4 중량부, 농글리세린 5.0, 선플라워 오일 10 중량부, 카르복시비닐폴리머 0.2 중량부, 산탄검 0.3중량부, 방부제를 통상의 방법으로 가열 용해시키고 이 용액에다 정제수 76.5 중량부를 가한 후 균질화기에서 유화시키고 나서 적당량의 향료를 가하고 다시 교반 혼합하여 표제의 제품을 얻었다. 이 제품은 고품질의 피부 미용제 및 피부 질환 개선제로 사용된다.1.7 parts by weight of cytosterol, 1.5 parts by weight of polyglyceryl 2-oleate, 0.7 parts by weight of ceramide, 1.2 parts by weight of ceteareth-4, and 1.5 parts by weight of cholesterol are homogenized at a constant temperature, 1 part by weight of saengsugung extract or herbal extract 0.4 parts by weight of dicetyl phosphate, 5.0 parts by weight of concentrated glycerin, 10 parts by weight of sunflower oil, 0.2 parts by weight of carboxyvinyl polymer, 0.3 parts by weight of xanthan gum, and a preservative by heating and dissolving it in a conventional manner, and then adding 76.5 parts by weight of purified water to the solution. After emulsifying in the air, an appropriate amount of perfume was added and stirred and mixed again to obtain the title product. This product is used as a high quality skin care agent and skin disease improver.
도 1은 난자 알부민과 수산화알루미늄을 복강 내 주사하고 포스페이트 버퍼 패취를 부착하여 아토피성 피부염을 유발한 BALB/C 생쥐에서 실험동물의 긁힘 횟수(scratching frequency)에 대한 대풍자 추출물의 효과를 나타낸 결과이고[A: 대풍자 추출물],1 is a result showing the effect of the macrosporum extract on the scratching frequency of the experimental animals in BALB / C mice induced with atopic dermatitis by intraperitoneal injection of egg albumin and aluminum hydroxide and attached to a phosphate buffer patch [ A: Satun Extract],
도 2는 난자 알부민과 수산화알루미늄을 복강 내 주사하고 포스페이트 버퍼 패취를 부착하여 아토피성 피부염을 유발한 BALB/C 생쥐에서 관능평가에 대한 대풍자 추출물의 효과를 관찰한 결과이고[A: 대풍자 추출물],FIG. 2 shows the results of observation of the effect of the macrosporum extract on sensory evaluation in BALB / C mice induced with atopic dermatitis by intraperitoneal injection of egg albumin and aluminum hydroxide and attachment of a phosphate buffer patch [A: macrosporus extract],
도 3은 난자 알부민과 수산화알루미늄을 복강 내 주사하고 포스페이트 버퍼 패취를 부착하여 아토피성 피부염을 유발한 BALB/C 생쥐에서 산호성 백혈구(eosinophil)와 Ig E 함량 변화에 대한 대풍자 추출물의 효과를 나타낸 결과이다[A: 대풍자 추출물].Fig. 3 shows the results of the macrophages extracts on the changes of eosinophil and Ig E contents in BALB / C mice induced with atopic dermatitis by intraperitoneal injection of egg albumin and aluminum hydroxide and attachment of phosphate buffer patches. [A: Satun Extract].
도 4는 난자 알부민과 수산화알루미늄을 복강 내 주사하고 포스페이트 버퍼 패취를 부착하여 아토피성 피부염을 유발한 BALB/C 생쥐에서 실험동물의 긁힘 횟수(scratching frequency)에 대한 5종의 생약 복합 추출물(UC1)의 효과를 60분 동안 관찰한 결과이고[A: 1, B: 3, C:7, D: 14],4 is a combination of five herbal extracts (UC1) for the scratching frequency of experimental animals in BALB / C mice induced with atopic dermatitis by intraperitoneal injection of egg albumin and aluminum hydroxide and attachment of a phosphate buffer patch. Was observed for 60 minutes [A: 1, B: 3, C: 7, D: 14],
도 5는 난자 알부민과 수산화알루미늄을 복강 내 주사하고 포스페이트 버퍼 패취를 부착하여 아토피성 피부염을 유발한 BALB/C 생쥐에서 관능평가에 대한 5종의 생약 복합 추출물(UC1)의 효과를 관찰한 결과이고[A: 1, B: 3, C:7, D: 14],FIG. 5 shows the results of observing the effects of five herbal extracts (UC1) on sensory evaluation in BALB / C mice induced with atopic dermatitis by intraperitoneal injection of egg albumin and aluminum hydroxide and attachment of a phosphate buffer patch. [A: 1, B: 3, C: 7, D: 14],
도 6은 난자 알부민과 수산화알루미늄을 복강 내 주사하고 포스페이트 버퍼 패취를 부착하여 아토피성 피부염을 유발한 BALB/C 생쥐에서 IgE와 IL4에 대한 5종의 생약 복합 추출물(UC1)의 효과를 관찰한 결과이고,FIG. 6 shows the effects of five herbal extracts (UC1) on IgE and IL4 in BALB / C mice induced with atopic dermatitis by intraperitoneal injection of egg albumin and aluminum hydroxide and attachment of phosphate buffer patches. ego,
도 7은 DNCB(1-chloro-2,4-dinitrobenzene)를 처리하여 아토피성 피부염을 유발한 NC/Nga 생쥐에서 실험동물의 긁힘 횟수(scratching frequency)에 대한 6종의 생약 복합 추출물(UC1)의 효과를 60분 동안 관찰한 결과이고[A: 1, B: 3, C:7],7 is a combination of six herbal extracts (UC1) for the scratching frequency of experimental animals in NC / Nga mice induced with atopic dermatitis by treatment with DNCB (1-chloro-2,4-dinitrobenzene) The effect was observed for 60 minutes [A: 1, B: 3, C: 7],
도 8은 DNCB를 처리하여 아토피성 피부염을 유발한 NC/Nga 생쥐에서 관능평가에 대한 6종의 생약 복합 추출물(UC1)의 효과를 60분 동안 관찰한 결과이며[A: 1, B: 3, C:7],FIG. 8 shows the effects of six herbal extracts (UC1) for 60 minutes on sensory evaluation in NC / Nga mice that induced atopic dermatitis by DNCB [A: 1, B: 3, C: 7],
도 9는 DNCB를 처리하여 아토피성 피부염을 유발한 NC/Nga 생쥐에서 IgE와 IL4에 대한 6종의 생약 복합 추출물(UC1)의 효과를 60분 동안 관찰한 결과이다.FIG. 9 shows the results of 60 minutes of the effects of six herbal extracts (UC1) on IgE and IL4 in NC / Nga mice that induce atopic dermatitis by DNCB treatment.
도 10은 난자 알부민과 수산화알루미늄을 복강 내 주사하고 포스페이트 버퍼 패취를 부착하여 아토피성 피부염을 유발한 BALB/C 생쥐에서 실험동물의 긁힘 횟수(scratching frequency)에 대한 19종의 생약 복합 추출물(C)의 효과를 나타낸 것이고[A: 1, B: 3, C:7, D: 14],Figure 10 is a combination of 19 herbal extracts (C) for the scratching frequency of experimental animals in BALB / C mice in which intraperitoneal injection of egg albumin and aluminum hydroxide and phosphate buffer patch induced atopic dermatitis [A: 1, B: 3, C: 7, D: 14],
도 11은 난자 알부민과 수산화알루미늄을 복강 내 주사하고 포스페이트 버퍼 패취를 부착하여 아토피성 피부염을 유발한 BALB/C 생쥐에서 관능평가에 대한 19종의 생약 복합 추출물(C)의 효과를 나타낸 것이다[A: 1, B: 3, C:7, D: 14].FIG. 11 shows the effect of 19 herbal extracts (C) on sensory evaluation in BALB / C mice induced with atopic dermatitis by intraperitoneal injection of egg albumin and aluminum hydroxide and attachment of a phosphate buffer patch [A : 1, B: 3, C: 7, D: 14].
Claims (16)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070123071 | 2007-11-29 | ||
KR20070123071 | 2007-11-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090056778A KR20090056778A (en) | 2009-06-03 |
KR100975426B1 true KR100975426B1 (en) | 2010-08-12 |
Family
ID=40988118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080032336A KR100975426B1 (en) | 2007-11-29 | 2008-04-07 | Composition comprising the crude extract for preventing and treating allergic skin diseases |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100975426B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2973697B1 (en) * | 2011-04-05 | 2013-10-25 | Nuxe Lab | COMPOSITION BASED ON OIL OF CHAULMOOGRA AND TRIBULUS TERRESTRIS FOR THE PIGMENTATION OF THE SKIN. |
CN108524700A (en) * | 2018-07-18 | 2018-09-14 | 荆门市玉英活全蝎生物技术研究所 | A kind of scorpion stilbene dermatitis liquid |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1240146A (en) * | 1999-04-29 | 2000-01-05 | 湖北三峡学院 | Medicine for treating skin ringworm and dermatitis and preparation process |
KR20040063127A (en) * | 1994-06-24 | 2004-07-12 | 파이토테크 리미티드 | Chinese herbs extract |
KR20040065498A (en) * | 2003-01-14 | 2004-07-22 | 주식회사 엘지생활건강 | Allergic dermatitis and skin itching relieving composition containing natural herb extract |
KR20070028944A (en) * | 2005-09-08 | 2007-03-13 | 주식회사 엔비젠 | Composition for treating and preventing atopic dermatitis and method for preparing thereof |
-
2008
- 2008-04-07 KR KR1020080032336A patent/KR100975426B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040063127A (en) * | 1994-06-24 | 2004-07-12 | 파이토테크 리미티드 | Chinese herbs extract |
CN1240146A (en) * | 1999-04-29 | 2000-01-05 | 湖北三峡学院 | Medicine for treating skin ringworm and dermatitis and preparation process |
KR20040065498A (en) * | 2003-01-14 | 2004-07-22 | 주식회사 엘지생활건강 | Allergic dermatitis and skin itching relieving composition containing natural herb extract |
KR20070028944A (en) * | 2005-09-08 | 2007-03-13 | 주식회사 엔비젠 | Composition for treating and preventing atopic dermatitis and method for preparing thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20090056778A (en) | 2009-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101382400B1 (en) | Composition comprising Protaetia brevitarsis for preventing and treating Inflammatory Disorder | |
WO2005072684A1 (en) | Process for producing maca extract | |
KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
JP4255432B2 (en) | Abnormal protein removal composition | |
JP2017532383A (en) | Composition comprising an extract or fraction of a genus Fox | |
EP1312373B1 (en) | Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same | |
JP2017197519A (en) | Composition for ameliorating climacteric symptoms or osteoporosis | |
JP2008308505A (en) | Composition for removing abnormal protein | |
JP6055667B2 (en) | Collagen production promoter | |
KR101330686B1 (en) | Composition for prevention or treatment of dermatitis Comprising an extract of herbal combination | |
KR20200140749A (en) | Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising Cudrania tricuspidata | |
KR100975426B1 (en) | Composition comprising the crude extract for preventing and treating allergic skin diseases | |
KR102142461B1 (en) | Composition for improving skin condition comprising extract of korean fir | |
JP6773362B2 (en) | Skin moisturizer for ingestion or administration | |
JP6541061B2 (en) | Composition for promoting clock gene expression | |
US20210177913A1 (en) | Use of hemolymph or hemolymph components for the treatment and prevention of inflammation and dry skin | |
JP6026257B2 (en) | Ceramide production promoter | |
KR20160081211A (en) | Composition for improving skin condition comprising extract of colored barley | |
KR101661423B1 (en) | anti-oxidant and anti-inflammation composition extracted from Isodon excisus, and its extracting method | |
KR20180133271A (en) | Preparations using herbal medicine extracts and powders and their manufacturing methods | |
KR102516129B1 (en) | A Cell protection composition comprising essential oil from fruits of medicinal plants | |
JP6288759B2 (en) | Transglutaminase activator | |
KR102450143B1 (en) | Composition for improving, preventing or treating skin disease comprising Thymus plant extract | |
JP7455350B2 (en) | Damage inhibitors, cosmetics, and food and beverages caused by air pollutants | |
KR101356213B1 (en) | Composition for preventing or treating allergy comprising nodakenin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130805 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140804 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150804 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160805 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170804 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180723 Year of fee payment: 9 |
|
R401 | Registration of restoration |